

RECEIVED
SEP 08 2021
BUREAU OF
LEGISLATIVE RESEARCH



**DRUG TESTING STANDARDS AND
PRACTICES PROGRAM.**

**Uniform Classification Guidelines for Foreign Substances
And Recommended Penalties Model Rule.**

December, 2020 (V.14.4)

© ASSOCIATION OF RACING COMMISSIONERS INTERNATIONAL – 2020.

Association of Racing Commissioners International
2365 Harrodsburg Road, Suite B-450, Lexington, Kentucky USA 40504 www.arci.com

Preamble to the Uniform Classification Guidelines of Foreign Substances

The Preamble to the Uniform Classification Guidelines was approved by the RCI Drug Testing and Quality Assurance Program Committee (now the Drug Testing Standards and Practices Program Committee) on August 26, 1991. Minor revisions to the Preamble were made by the Drug Classification subcommittee (now the Veterinary Pharmacologists Subcommittee) on September 3, 1991.

"The Uniform Classification Guidelines printed on the following pages are intended to assist stewards, hearing officers and racing commissioners in evaluating the seriousness of alleged violations of medication and prohibited substance rules in racing jurisdictions. Practicing equine veterinarians, state veterinarians, and equine pharmacologists are available and should be consulted to explain the pharmacological effects of the drugs listed in each class prior to any decisions with respect to penalties to be imposed. The ranking of drugs is based on their pharmacology, their ability to influence the outcome of a race, whether or not they have legitimate therapeutic uses in the racing horse, or other evidence that they may be used improperly. These classes of drugs are intended only as guidelines and should be employed only to assist persons adjudicating facts and opinions in understanding the seriousness of the alleged offenses. The facts of each case are always different and there may be mitigating circumstances which should always be considered. These drug classifications will be reviewed frequently and new drugs will be added when appropriate."

Notes Regarding Classification Guidelines

- Where the use of a drug is specifically permitted by a jurisdiction, then the jurisdiction's rule supersedes these penalty guidelines.
- Regulators should be aware that a laboratory report may identify a drug only by the name of its metabolite. The metabolite might not be listed here, but the parent compound may be.
- These classes of drugs are intended only as guidelines and should be employed only to assist persons adjudicating facts and opinions in understanding the seriousness of the alleged offenses.
- The facts of each case are different and there may be mitigating circumstances that should be considered.
- These drug classifications will be reviewed periodically. New drugs will be added or some drugs may be reclassified when appropriate.
- Racing Commissioners International (RCI) and/or the Racing Medication and Testing Consortium (RMTC) should be consulted for found substances or drugs not included in these guidelines and treated as Class 1 violations warranting a Class A penalty unless otherwise advised.

Classification Criteria

The RCI Drug Classification Scheme is based on 1) pharmacology, 2) drug use patterns, and 3) the appropriateness of a drug for use in the racing horse. Categorization is decided using the following general guidelines:

- **Pharmacology.** Drugs that are known to be potent stimulants or depressants are placed in higher classes, while those that have (or would be expected to have) little effect on the outcome of a race are placed in lower classes.

- **Drug Use Patterns.** Some consideration is given to placement of drugs based on practical experience with their use and the nature of positive tests. For example, procaine positives have in the past been associated primarily with the administration of procaine penicillin, and this has been taken into consideration in the placement of procaine into Class 3 instead of Class 2 with other injectable local anesthetics.
- **Appropriateness of Drug Use.** Drugs that clearly are intended for use in equine therapeutics are placed in lower classes. Drugs that clearly are not intended for use in the horse are placed in higher classes, particularly if they might affect the outcome of a race. Drugs that are recognized as legitimately useful in equine therapeutics but could affect the outcome of a race are placed in the middle or higher classes.

The list includes most drugs that have been reported as detected by racing authority laboratories in the United States, Canada, the United Kingdom and other Association of Official Racing Chemists (AORC) laboratories, but does not include those which would seem to have no effect on the performance of the horse or drug detectability. For example, it does not include antibiotics, sulfonamides, vitamins, anthelmintics, or pangamic acid, all of which have been reported.

The list contains many drugs that have never been reported as detected. Usually, these are representatives of chemical classes that have the potential for producing an effect, and in many cases, for which at least one drug in that chemical class has been reported.

Most drugs have numerous effects, and each was judged on an individual basis. There are instances where there is a rather fine distinction between drugs in one category and those in the next. This is a reflection of a nearly continuous spectrum of effects from the most innocuous drug on the list to the drug that is the most offensive.

Classification Definitions

- **Class 1:** Stimulant and depressant drugs that have the highest potential to affect performance and that have no generally accepted medical use in the racing horse. Many of these agents are Drug Enforcement Agency (DEA) schedule II substances. These include the following drugs and their metabolites: Opiates, opium derivatives, synthetic opioids and psychoactive drugs, amphetamines and amphetamine-like drugs as well as related drugs, including but not limited to apomorphine, nikethamide, mazindol, pemoline, and pentylentetrazol. Though not used as therapeutic agents, all DEA Schedule 1 agents are included in Class 1 because they are potent stimulant or depressant substances with psychotropic and often habituating actions. This class also includes all erythropoietin stimulating substances and their analogues.
- **Class 2:** Drugs that have a high potential to affect performance, but less of a potential than drugs in Class 1. These drugs are 1) not generally accepted as therapeutic agents in racing horses, or 2) they are therapeutic agents that have a high potential for abuse. Drugs in this class include: psychotropic drugs, certain nervous system and cardiovascular system stimulants, depressants, and neuromuscular blocking agents. Injectable local anesthetics are included in this class because of their high potential for abuse as nerve blocking agents.
- **Class 3:** Drugs that may or may not have generally accepted medical use in the racing horse, but the pharmacology of which suggests less potential to affect performance than drugs in Class 2. Drugs in this class include bronchodilators, anabolic steroids and other drugs with primary effects on the autonomic nervous system, procaine, antihistamines with sedative properties and the high-ceiling diuretics.

- **Class 4:** This class includes therapeutic medications that would be expected to have less potential to affect performance than those in Class 3. Drugs in this class includes less potent diuretics; corticosteroids; antihistamines and skeletal muscle relaxants without prominent central nervous system (CNS) effects; expectorants and mucolytics; hemostatics; cardiac glycosides and anti-arrhythmics; topical anesthetics; antidiarrheals and mild analgesics. This class also includes the non-steroidal anti-inflammatory drugs (NSAIDs), at concentrations greater than established limits.
- **Class 5:** This class includes those therapeutic medications that have very localized actions only, such as anti-ulcer drugs, and certain anti-allergic drugs. The anticoagulant drugs are also included.
- **Prohibited Practices:**
 - A) The possession and/or use of a drug, substance or medication, specified below, on the premises of a facility under the jurisdiction of the regulatory body for which a recognized analytical method has not been developed to detect and confirm the administration of such substance; or the use of which may endanger the health and welfare of the horse or endanger the safety of the rider or driver; or the use of which may adversely affect the integrity of racing:
 - 1) Erythropoietin
 - 2) Darbepoetin
 - 3) Oxyglobin
 - 4) Hemopure
 - B) The possession and/or use of a drug, substance, or medication on the premises of a facility under the jurisdiction of the regulatory body that has not been approved by the United States Food and Drug Administration (FDA) for use in the United States.
 - C) The practice, administration, or application of a treatment, procedure, therapy or method identified below, which is performed on the premises of a facility under jurisdiction of a regulatory body and which may endanger the health and welfare of the horse or endanger the safety of the rider or driver, or the use of which may adversely affect the integrity of racing:

Drug Classification Scheme

- **Class 1:** Opiates, opium derivatives, synthetic opioids, psychoactive drugs, amphetamines, and all DEA Schedule I substances (see <http://www.deadiversion.usdoj.gov/schedules/#list>), and many DEA Schedule II drugs. Also found in this class are drugs that are potent stimulants of the CNS. Drugs in this class have no generally accepted medical use in the racing horse and their pharmacologic potential for altering the performance of a racing horse is very high. This class also includes all erythropoietin stimulating substances and their analogues.
 - **Class 2:** Drugs placed in this category have a high potential for affecting the outcome of a race. Most are not generally accepted as therapeutic agents in the racing horse. Many are products intended to alter consciousness or the psychic state of humans, and have no approved or indicated use in the horse. Some, such as injectable local anesthetics, have legitimate use in equine medicine, but should not be found in a racing horse. The following groups of drugs are placed in this class:
 - A) Opiate partial agonists, or agonist-antagonists.
 - B) Non-opiate psychotropic drugs. These drugs may have stimulant, depressant, analgesic or neuroleptic effects.
 - C) Miscellaneous drugs, which might have a stimulant effect on the CNS.
 - D) Drugs with prominent CNS depressant action.
 - E) Anti-depressant and antipsychotic drugs, with or without prominent CNS stimulatory or depressant effects.
 - F) Muscle blocking drugs - those that have a direct neuromuscular blocking action.
 - G) Local anesthetics that have a reasonable potential for use as nerve-blocking agents (except procaine).
 - H) Snake venoms and other biologic substances that may be used as nerve-blocking agents.
 - **Class 3:** Drugs placed in this class may or may not have an accepted therapeutic use in the horse. Many are drugs that affect the cardiovascular, pulmonary and autonomic nervous systems. They all have the potential of affecting the performance of a racing horse. The following groups of drugs are placed in this class:
 - A) Drugs affecting the autonomic nervous system that do not have prominent CNS effects, but which do have prominent cardiovascular or respiratory system effects. Bronchodilators are included in this class.
 - B) A local anesthetic that has nerve-blocking potential but also has a high potential for producing urine residue levels from a method of use not related to the anesthetic effect of the drug (procaine).
 - C) Miscellaneous drugs with mild sedative action, such as the sleep-inducing antihistamines.
 - D) Primary vasodilating/hypotensive agents.
 - E) Potent diuretics affecting renal function and body fluid composition.
 - F) Anabolic and/or androgenic steroids and other drugs.
-
- **Class 4:** Drugs in this category comprise primarily therapeutic medications routinely used in racehorses. These may influence performance, but generally have a more limited ability to do so. Groups of drugs assigned to this category include the following:

- A) Non-opiate drugs that have a mild central antipyretic effect.
- B) Drugs affecting the autonomic nervous system that do not have prominent CNS, cardiovascular, or respiratory effects:
 - 1) Drugs used solely as topical vasoconstrictors or decongestants.
 - 2) Drugs used as gastrointestinal antispasmodics.
 - 3) Drugs used to void the urinary bladder.
 - 4) Drugs with a major effect on CNS vasculature or smooth muscle of visceral organs.
- C) Antihistamines that do not have a significant CNS depressant effect. This does not include the H₂ blocking agents, which are in Class 5.
- D) Mineralocorticoid drugs.
- E) Skeletal muscle relaxants.
- F) Anti-inflammatory drugs. These drugs may reduce pain as a consequence of their anti-inflammatory action.
 - 1) Non-steroidal anti-inflammatory drugs (NSAIDs). (Aspirin-like drugs).
 - 2) Corticosteroids (glucocorticoids).
 - 3) Miscellaneous anti-inflammatory agents. G. Less potent diuretics.
- H. Cardiac glycosides and antiarrhythmic agents.
 - 1. Cardiac glycosides.
 - 2. Antiarrhythmic agents (exclusive of lidocaine, bretylium, and propranolol).
 - 3. Miscellaneous cardiotonic drugs.
- I. Topical Anesthetics - agents not available in injectable formulations.
- J. Antidiarrheal drugs.
- K. Miscellaneous drugs:
 - 1. Expectorants with little or no other pharmacologic action.
 - 2. Stomachics.
 - 3. Mucolytic agents.

- **Class 5:** Drugs in this category are therapeutic medications that have very localized actions only, such as anti-ulcer drugs, and certain antiallergic drugs. The anticoagulant drugs are also included.

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
----------------	---------------	------------	---------------	------------------	-------

Δ-1-androstene-3, 17diol		3	A		
Δ-1-androstene-3, 17dione		3	A		
Δ-1-dihydrotestosterone		3	A		
1-androstenediol (5αandrost-1-ene-3β, 17βdiol)		3	B	Steroid - endogenous weak androgen steroid hormone and intermediate in the biosynthesis of testosterone from dehydroepiandrosterone (DHEA) and of estrone.	Endogenous AAS
1-androstenedione (5αandrost-1-ene-3, 17dione)		3	B	Steroid - endogenous weak androgen steroid hormone and intermediate in the biosynthesis of testosterone from dehydroepiandrosterone (DHEA) and of estrone.	Endogenous AAS
1-testosterone (17βhydroxy-5α-androst-1-en-3-one)		3	A	Steroid - chemically related to anabolic steroids.	AAS lacking FDA approval
19-Norandrostenediol		3	B		
19-Norandrostenedione		3	B		
19-noretiocholanolone		3	B	Nandrolone Link - a metabolite of nandrolone (19-nortestosterone) and bolandione (19norandrostenedione).	Metabolite of a B substance
2-Aminoheptane	<i>Tuamine</i>	4	B		
3-Methoxytyramine	<i>3-MT</i>	2	A		
3,4-methylenedioxypyprovalerone	<i>MDPV, "bath salts"</i>	1	A		

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
----------------	---------------	------------	---------------	------------------	-------

<i>4-androstene-3,6,17-trione (6-oxo)</i>		3	B	Hormone and Metabolic effects, same classification as Testolactone on Human Olympic Guidelines - Aromatase inhibitors.	Testolactone has B classification
<i>4-androstenediol (androst-4-ene-3β,17βdiol)</i>		3	B	Testosterone Link - androstenediol that is converted to testosterone	Metabolized to a B substance
4-Hydroxytestosterone		3	B		
<i>5-androstenedione (androst-5-ene-3,17dione)</i>		3	B	Testosterone Link - prohormone of testosterone	Metabolized to a B substance
<i>5α-androstane-3α,17αdiol</i>		3	B	Testosterone Link - testosterone metabolite.	Metabolite of a B substance
<i>5α-androstane-3α,17βdiol</i>		3	B	Testosterone Link - testosterone metabolite	Metabolite of a B substance
<i>5α-androstane-3β,17αdiol</i>		3	B	Testosterone Link - testosterone metabolite.	Metabolite of a B substance
<i>5α-androstane-3β,17βdiol</i>		3	B	Testosterone Link - testosterone metabolite	Metabolite of a B substance
<i>5β-androstane-3α,17βdiol, androst-4-ene3α,17α-diol</i>		3	B	Testosterone Link - androstenediol that is converted to testosterone.	Metabolized to a B substance
<i>7-keto-dhea;19-</i>		3	B	DHEA Link - a steroid produced by metabolism of the prohormone dehydroepiandrosterone (DHEA).	Metabolite of a B substance
<i>7α-hydroxy-dhea</i>		3	B	DHEA Link - naturally occurring steroid and a major metabolite of dehydroepiandrosterone (DHEA).	Metabolite of a B substance
<i>7β-hydroxy-dhea</i>		3	B	DHEA Link - naturally occurring steroid and a major metabolite of dehydroepiandrosterone (DHEA).	Metabolite of a B substance
a-Cobratoxin		1	A		
Acebutolol	<i>Sectral</i>	3	B		

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
Accecarbromal		2	A		
Acenocoumarol		5	C		
Acepromazine	<i>Atrovet, Notensil, PromAce®</i>	3	B		
Acetaminophen (Paracetamol)	<i>Tylenol, Tempra, etc.</i>	4	C		
Acetanilid		4	B		
Acetazolamide	<i>Diamox, Vetamox</i>	4	C		
Acetophenazine	<i>Tindal</i>	2	A		
Acetophenetidin (Phenacetin)		4	B		
Acetylcysteine		4	C		
Acetylsalicylic acid (Aspirin)		4	C		
Activators of the AMP-activated protein kinase (AMPK) - E.g., AICAR, and Peroxisome Proliferator Activated Receptor δ (ppar δ) agonists (e.g., GW 1516).	AICAR	2	A	Hormone and Metabolic effects, same classification as Testolactone on Human Olympic Guidelines.	PPARs are experimental drugs without FDA approval
Adinazolam		2	A		
Adrenochrome monosemicarbazone salicylate		4	B		
Albuterol (Salbutamol)	<i>Proventil, Ventolin</i>	3	B	NOTE: "A" penalty for quarter horse races.	
Alclofenac		2	B		
Alclometasone	<i>Aclovate</i>	4	C		
Alcuronium	<i>Alloferin</i>	2	A		

Aldosterone	<i>Aldocortin, Electro cortin</i>	4	B		
--------------------	-----------------------------------	---	---	--	--

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
Alfentanil	<i>Alfenta</i>	1	A		
Almotriptan	<i>Axert</i>	3	A		
Alphaprodine	<i>Nisentil</i>	2	A		
Alpha-pyrrolidinovalerophenone (also known as Alpha PVP)		1	A	Known as bath salts in humans	
Alpidem	<i>Anaxyl</i>	2	A		
Alprazolam	<i>Xanax</i>	2	A		
Alprenolol		2	A		
Althesin	<i>Saffan</i>	2	A		
Altrenogest	<i>Regumate</i>	4	C	*Classification for geldings, colts, adult intact males, spayed females only.	
Ambenonium	<i>Mytelase, Myeuran</i>	3	B		
Ambroxol	<i>Ambiril, etc.</i>	4	B		
Amcinonide	<i>Cyclocort</i>	4	C		
Amiloride	<i>Moduretic; Midamor</i>	4	B		
Aminocaproic acid	<i>Amicar, Caprocid</i>	4	C		
Aminoglutethimide		3	B	Hormone and Metabolic effects, same classification as Testolactone on Human Olympic Guidelines.	Testolactone has B classification
Aminophylline	<i>Aminophyllin, etc.</i>	3	B		
Aminopyrine		4	B		
Aminorex	<i>Aminoxafen, Aminoxaphen, Apiquel, McN-742, Menocil</i>	1	A		

Amiodarone		4	B		
Amisometradine	<i>Rolictron</i>	4	B		
Amisulpride	<i>Solian</i>	2	A		
Amitraz	<i>Mitaban</i>	3	B		

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note
Amitriptyline	<i>Elavil, Amitril, Endep</i>	2	A		
Amlodipine	<i>Ammivin, Norvasc</i>	3	B		
Amobarbital	<i>Amytal</i>	2	A		
Amoxapine	<i>Asendin</i>	2	A		
Amperozide		2	A		
Amphetamine		1	A		
Amrinone		4	B		
Amyl nitrite		2	A		
Anastrozole		3	B	Hormone and Metabolic effects, same classification as Testolactone on Human Olympic Guidelines - Aromatase inhibitors.	Testolactone has B classification
Andarine		2	A		SARM
Androst-4-ene-3α,17βdiol		3	B	Testosterone Link - an androstenediol that is converted to testosterone.	Metabolized to a B substance
Androst-4-ene-3β,17αdiol		3	B	Testosterone Link - an androstenediol that is converted to testosterone.	Metabolized to a B substance
Androst-5-ene-3α,17αdiol		3	B	Testosterone Link - androstenediol that is converted to testosterone	Metabolized to a B substance

<i>Androst-5-ene-3α,17βdiol</i>		3	B	Testosterone Link - prohormone of testosterone.	Metabolized to a B substance
<i>Androst-5-ene-3β,17αdiol</i>		3	B	Testosterone Link - prohormone of testosterone.	Metabolized to a B substance
<i>Androsta-1,4,6-triene-3,17-dione (androstatienedione)</i>		3	B	Hormone and Metabolic effects, same classification as Testolactone on Human Olympic Guidelines - Aromatase inhibitors.	Testolactone has B classification

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
Androstenediol (androst-5-ene-3 β ,17 β diol)		3	B	Steroid: weak androgen and estrogen steroid hormone and intermediate in the biosynthesis of testosterone from dehydroepiandrosterone (DHEA)	Metabolite of a B substance
Androstenedione (androst-4-ene-3,17dione)		3	B	Steroid: endogenous weak androgen steroid hormone and intermediate in the biosynthesis of testosterone from dehydroepiandrosterone (DHEA) and of estrone.	Endogenous AAS
<i>Androsterone (3βhydroxy-5α-androstan-17-one)</i>		3	B	Testosterone Link - a metabolite of testosterone and dihydrotestosterone (DHT)	Metabolite of a B substance
Anileridine	<i>Leritine</i>	1	A		
Anilopam	<i>Anisine</i>	2	A		
Anisindione		5	D		
Anisotropine	<i>Valpin</i>	4	B		
Antipyrine		4	B		
Apazone (Azapropazone)	<i>Rheumox</i>	4	B		

Apomorphine		1	A		
Aprindine		4	B		
Aprobarbital	<i>Alurate</i>	2	A		
ARA-290		1	A	Erythropoietin Link - a nonerythropoietic peptide engineered from erythropoietin.	Blood doping agent
Arecoline		3	A		
Arformoterol		3	B		
Aripiprazole	<i>Abilify</i>	2	A		
Arsenic		3	B	Arsenic is present in pressure-treated lumber designated for non-residential use. Cribbing or wood chewing may result in exposure sufficient to result in concentrations in excess of the screening limit. Findings for arsenic warrant investigation into the route of exposure with mitigation to 3/C recommended when there is compelling evidence for environmental exposure rather than deliberate administration.	

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
<i>Aromatase inhibitors listed:</i>					
Articaine	<i>Septocaine; Ultracaine,</i>	2	B		

<i>Asialo EPO</i>		1	A	Erythropoietin Link - desialylated form of human glycoprotein hormone erythropoietin (EPO), which has been reported to be neuro-, cardio-, and renoprotective in animal models of organ injuries.	Blood doping agent
Atenolol	<i>Tenormin</i>	3	B		
Atipamazole		2	B		
Atomoxetine	<i>Strattera</i>	2	A		
Atracurium	<i>Tracrium</i>	2	A		
Atropine		3	B		
Azacylonol	<i>Frenque</i>	2	A		
Azaperone	<i>Stresnil, Suicalm, Fentaz (with Fentanyl)</i>	2	A		
Baclofen	<i>Lioresal</i>	4	B		
Barbital	<i>Veronal</i>	2	A		
Barbiturates		2	A		
Beclomethasone	<i>Propaderm</i>	4	C		
Bemegride	<i>Megimide, Mikedimide</i>	2	A		
Benazepril	<i>Lotrel, Lotensin</i>	3	A		
Bendroflumethiazide	<i>Naturetin</i>	4	B		
Benoxaprofen		2	B		
Benoxinate	<i>Dorsacaine</i>	4	C		

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
Benperidol	<i>Anquil</i>	2	A		

Benzazepam	<i>Tiadipona</i>	2	A		
Benzactizine	<i>Deprol, Bronchodiletten</i>	2	A		
Benzocaine		4	B		
Benzoctamine		2	A		
Benzodiazepines		2	A		
Benzonatate	<i>Tessalon, Tessalon Perles, Zonatuss</i>	2	A		
Benzphetamine	<i>Didrex</i>	2	A		
Benzthiazide		4	B		
Benztropine	<i>Cogentin</i>	2	A		
Benzylpiperazine (BZP)		1	A		
Bepridil	<i>Bepadin</i>	4	B		
Betamethasone	<i>Betasone, etc.</i>	4	C		
Betaxolol	<i>Kerlone</i>	3	B		
Bethanechol	<i>Urecholine, Duvoid</i>	4	C		
Bethanidine	<i>Esbatal</i>	3	A		
Biperiden	<i>Akineton</i>	3	A		
Biriperone		2	A		
Bisoprolol	<i>Zebeta, Bisobloc, etc.</i>	3	B		
Bisphosphonates (any)		3	A		
Bitolterol	<i>Effectin</i>	3	A		

Bolandiol (estr-4-ene3β, 17β-diol)		3	A	Steroid	AAS lacking FDA approval
---	--	---	---	---------	--------------------------

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note
Bolasterone		3	A		
Boldenone	<i>Equipoise</i>	3	B		
Boldione		3	A		
Botulinum toxin		2	A		
Bretylum	<i>Bretylol</i>	3	B		
Brimonidine	<i>Alphagan</i>	2	A		
Bromazepam	<i>Lexotan, Lectopam</i>	2	A		
Bromfenac	<i>Duract</i>	3	A		
Bromhexine	<i>Oletor, etc.</i>	4	B		
Bromisovalum	<i>Diffucord, etc.</i>	2	A		
Bromocriptine	<i>Parlodel</i>	2	A		
Bromodiphenhydramine		3	B		
Bromperidol	<i>Bromidol</i>	2	A		
Brompheniramine	<i>Dimetane, Disomer</i>	3	B		
Brotizolam	<i>Brotocol</i>	2	A		
Budesonide	<i>Pulmacort, Rhinocort</i>	4	C		
Bufexamac		3	A		
Bumetanide	<i>Bumex</i>	3	B		
Bupivacaine	<i>Marcaine</i>	2	A		

Buprenorphine	<i>Temgesic</i>	2	A		
Bupropion	<i>Wellbutrin</i>	2	A		
Buspirone	<i>Buspar</i>	2	A		

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
Butabarbital (Secbutobarbitone)	<i>Butacaps, Butasol, etc.</i>	2	A		
Butacaine	<i>Butyn</i>	2	A		
Butalbital (Talbutal)	<i>Fiorinal</i>	2	A		
Butamben (butyl aminobenzoate)	<i>Butesin</i>	4	C		
Butanilicaine	<i>Hostacain</i>	2	A		
Butaperazine	<i>Repoise</i>	2	A		
Butoctamide	<i>Listomin</i>	2	A		
Butorphanol	<i>Stadol, Torbugesic</i>	3	B		
Butoxycaine	<i>Stadacain</i>	4	B		
Caffeine		2	B		
Calusterone	<i>Methosorb</i>	3	A		
Camazepam	<i>Paxor</i>	2	A		
Camphor		4	C		
Candesartan	<i>Atcand</i>	3	B		
Cannabidiol (CBD)¹	Anti-epileptic, analgesic	2	B		
Canrenone		4	C	Metabolite of a C substance - steroidal antimineralocorticoid, active metabolite of spironolactone (a diuretic).	
Capsaicin		2	B		

Captodiamine	<i>Covatine</i>	2	A		
Captopril	<i>Capoten</i>	3	B		
Carazolol	<i>Carbacel, Conducton</i>	3	A		
Carbachol	<i>Lentin, Doryl</i>	3	B		
Carbamezapine	<i>Tegretol</i>	3	B		

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
Carbamylated EPO		1	A	Erythropoietin Link - may be a beneficial tissueprotective cytokine.	Blood doping agent
Carbazochrome		4	B		
Carbidopa + levodopa	<i>Sinemet</i>	2	A		
Carbinoxamine	<i>Clistin</i>	3	B		
Carbromol	<i>Mifudorm</i>	2	A		
Cardarine (GW-501516)		2	A	No legit use in the racehorse. Lacks FDA approval	
Carfentanil		1	A		
Carisoprodol	<i>Rela, Soma</i>	2	B		
Carphenazine	<i>Proketazine</i>	2	A		
Carpipramine	<i>Prazinil</i>	2	A		
Carprofen	<i>Rimadyl</i>	4	B		
Carteolol	<i>Cartrol</i>	3	B		
Carticaine (see articaine)	<i>Septocaine; Ultracaine, etc.</i>	2	B		
Carvedilol	<i>Coreg</i>	3	B		
Cathinone	<i>khat, kat, qat, quat, chat, catha, Abyssinian tea, African tea</i>	1	A		

Celecoxib	<i>Celebrex</i>	3	B		
Cetirizine	<i>Zyrtec</i>	4	C		
Chloral betaine	<i>Beta-Chlor</i>	2	A		
Chloral hydrate	<i>Nactec, Oridrate, etc.</i>	2	A		
Chloraldehyde (chloral)		2	A		
Chloralose (AlphaChloralose)		2	A		

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
Chlordiazepoxide	<i>Librium</i>	2	A		
Chlorhexidol		2	A		
Chlormerodrin	<i>Neohydrin</i>	4	B		
Chlormezanone	<i>Trancopal</i>	2	A		
Chloroform		2	A		
Chlorophenesin	<i>Maolate</i>	4	C		
Chloroprocaine	<i>Nesacaine</i>	2	A		
Chloroquine	<i>Avloclor</i>	4	C		
Chlorothiazide	<i>Diuril</i>	4	B		
Chlorpheniramine	<i>Chlortrimeton, etc.</i>	4	B		
Chlorproethazine	<i>Newiplege</i>	2	A		
Chlorpromazine	<i>Thorazine, Largactil</i>	1	A		
Chlorprothixene	<i>Taractan</i>	2	A		

Chlorthalidone	<i>Hydron</i>	4	B		
Chlorzoxazone	<i>Paraflex</i>	4	B		
Chorionic Gonadotropin (CG)		3	B	Hormone and behavioral effects - a water soluble glycoprotein derived from human pregnancy urine. Used for behavior modification in colts / horses. There should be no restriction/regulation in fillies and mares.	
Ciclesonide		4	C		
Cilostazol	<i>Pletal</i>	4	B		
Cimeterol		3	A		
Cimetidine	<i>Tagamet</i>	5	D		
Cinchocaine	<i>Nupercaine</i>	2	B		

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
Citalopram	<i>Celex</i>	2	A		
Clanobutin		4	B		
Clemastine	<i>Tavist</i>	3	B		
Clenbuterol	<i>Ventipulmin</i>	3	B	NOTE: "A" penalty for quarter horse races.	
Clibucaine	<i>Batrax</i>	2	A		
Clidinium	<i>Quarezan, Clindex, etc.</i>	3	B		
Clobazam	<i>Urbanyl</i>	2	A		
Clobetasol	<i>Temovate</i>	4	C		
Clocapramine		2	A		
Clocortolone	<i>Cloderm</i>	4	C		
Clodronate	<i>OsPhos</i>	3	A	Bisphosphonate	

Version 14.4, December 2020

Clofenamide		4	B		
Clomethiazole (Chlormethiazole)		2	A		
Clomiphene		3	B	Hormone and Metabolic effects, same classification as Testolactone on Human Olympic Guidelines - Estrogen modulator.	Testolactone has B classification
Clomipramine	Anafranil	2	A		
Clonazepam	Klonopin	2	A		
Clonidine	Catapres	3	B		
Clorazepate	Tranxene	2	A		
Clormecaine	Placacid	2	A		
Clostebol		3	A		

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
Clothiapine	Entermin	2	A		
Clotiazepam	Trecalmo, Rize	2	A		
Cloxacolam	Enadel, Sepazon, Toleston	2	A		
Clozapine	Clozaril, Leponex	2	A		
CNTO 530		1	A	Erythropoietin Link - a biopharmaceutical consisting of a novel peptide that mimics the actions of erythropoietin, CNTO 530 produced sustained increases in red blood cell parameters.	Blood doping agent

Cobalt (check note)		3	B1	For cobalt concentrations of less than 25 parts per billion (ppb) of blood serum or plasma no penalty is recommended. For concentrations of 25 ppb or greater but less than 50 ppb of blood plasma or serum the recommended penalty is a written warning, the placement of the horse on the Veterinarians List with removal from list only after a blood test confirms that the concentration is below 25 ppb of blood plasma or serum. Testing shall be paid by the owner(s) of the horse. Concentrations of 50 ppb or greater in blood plasma or serum have a recommended "B" penalty.	
Cocaine		1	A3	If it is determined by the State Veterinarian/Equine Medical Director, the Stewards, or the Racing Authority that the finding of cocaine or morphine was unintentional and not based upon an attempt to affect the outcome of a race, the Stewards or Racing Authority may elect to assign a Class B penalty to the trainer.	
Codeine		1	A		
Colchicine		4	B		
Conorphone		2	A		
Corticaine	<i>Ultracain</i>	2	A		
Corticotrophind		3	B	Peptide hormone involved in the stress response.	
Cortisone	<i>Cortone, etc.</i>	4	C		
Cromolyn	<i>Intel</i>	5	D		

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
Crotetamide		2	A		
Cyamemazine	<i>Tercian</i>	2	A		
Cyclandelate	<i>Cyclospasmol</i>	3	A		
Cyclizine	<i>Merazine</i>	3	B		
Cyclobarbital	<i>Phanodorm</i>	2	A		
Cyclobenzaprine	<i>Flexeril</i>	4	B		

Cyclofenil		3	B	Hormone and Metabolic effects, same classification as Testolactone on Human Olympic Guidelines - selective estrogen receptor modulator (SERM).	Testolactone has B classification
Cyclomethycaine	<i>Surfacaine</i>	4	C		
Cyclothiazide	<i>Anhydron, Renazide</i>	4	B		
Cyrimine	<i>Pagitan</i>	3	B		
Cyproheptadine	<i>Periactin</i>	3	B		
Danazol	<i>Danocrine</i>	3	B		
Dantrolene	<i>Dantrium</i>	4	C		
Darbepoetin	<i>Aranesp</i>	1	A		
Darbepoetin (depo)		1	A	Erythropoietin Link - Bone marrow stimulant (Erythropoiesis stimulating agents are medications which stimulates the bone marrow to make red blood cells).	Blood doping agent
Decamethonium	<i>Syncurine</i>	2	A		
Dehydrochloromethyltestosterone		3	A		

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
Dembroxol (Dembrexine)	<i>Spirolysin</i>	4	C		
Demoxepam		2	A		
Deoxycorticosterone	<i>Percortin, DOCA, Descotone, Dorcostrin</i>	4	C		
Deracoxib	<i>Deremacc</i>	3	B		
Dermorphin		1	A		

Desipramine	<i>Norpromine, Pertofrane</i>	2	A		
Desonide	<i>Des Owen</i>	4	C		
Desoximetasone	<i>Topicort</i>	4	C		
Desoxymethyltestosterone		3	A		
Detomidine	<i>Dormosedan</i>	3	B		
Dexamethasone	<i>Azium, etc</i>	4	C		
Dextromethorphan		4	B		
Dextromoramide	<i>Palfium, Narcolo</i>	1	A		
Dextropropoxyphene	<i>Darvon</i>	3	B		
Dezocine	<i>Dalgan</i>	2	A		
Diamorphine		1	A		
Diazepam	<i>Valium</i>	2	B		
Diazoxide	<i>Proglycem</i>	3	B		
Dibucaine	<i>Nupercainal, Cinchocaine</i>	2	B		
Dichloralphenazone	<i>Febenol, Isocom</i>	2	A		
Dichlorphenamide	<i>Daramide</i>	4	C		
Diclofenac	<i>Voltaren, Voltarol</i>	4	C		

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
Dicumarol	<i>Dicumarol</i>	5	D		
Diethylpropion	<i>Tepanil, etc.</i>	2	A		
Diethylthiambutene	<i>Themalon</i>	2	A		

Diflorasone	<i>Florone, Maxiflor</i>	4	C		
Diffucortolone	<i>Flu-Cortinest, etc.</i>	4	C		
Diflunisal		3	B		
Digitoxin	<i>Crysdigin</i>	4	B		
Digoxin	<i>Lanoxin</i>	4	B		
Diisopropylamine		2	B	Consistent with nitroglycerine	
Dihydrocodeine	<i>Parcodin</i>	2	A		
Dihydroergotamine		4	B		
Dihydrotestosterone (17β-hydroxy-5αandrostane-3-one)		3	B	Steroid - endogenous androgen sex steroid and hormone.	Endogenous AAS
Dilorazepam	<i>Briantum</i>	2	A		
Diltiazem	<i>Cardizem</i>	4	B		
Dimeflin		3	A		
Dimethisoquin	<i>Quotane</i>	4	B		
Dimethylsulfoxide (DMSO)	<i>Domoso</i>	4	C		
Diphenadione		5	C		
Diphenhydramine	<i>Benadryl</i>	3	B		
Diphenoxylate	<i>Difenoxin, Lomotil</i>	4	B		
Diprenorphine	<i>MSO/50</i>	2	A		
Dipyridamole	<i>Persantine</i>	3	B		

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
----------------	---------------	------------	---------------	------------------	-------

Dipyrene	<i>Novin, Methampyrone</i>	4	C		
Disopyramide	<i>Norpace</i>	4	B		
Divalproex	<i>Depakote</i>	3	A		
Dixyrazine	<i>Esucos</i>	2	A		
Dobutamine	<i>Dobutrex</i>	3	B		
Donepezil	<i>Aricept</i>	1	A		
Dopamine	<i>Intropin</i>	2	A		
Doxacurium	<i>Nuromax</i>	2	A		
Doxapram	<i>Dopram</i>	2	A		
Doxazosin		3	A		
Doxefazepam	<i>Doxans</i>	2	A		
Doxepin	<i>Adapin, Sinequan</i>	2	A		
Doxylamine	<i>Decapryn</i>	3	B		
Dromostanolone	<i>Drolban</i>	3	B		
Droperidol	<i>Inapsine, Droleptan, Innovar-Vet (with Fentanyl)</i>	2	A		
Drostanolone		3	A	Steroid	AAS lacking FDA approval
Duloxetine		2	A		
Dyclonine	<i>Dyclone</i>	4	C		
Dyphylline		3	B		
Edrophonium	<i>Tensilon</i>	3	B		
Eletripan	<i>Relpax</i>	3	A		

Eltenac		4	B		
---------	--	---	---	--	--

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
Enalapril (metabolite enalaprilat)	<i>Vasotec</i>	3	A		
Enciprazine		2	A		
Endorphins		1	A		
Enkephalins		1	A		
Ephedrine		2	A		
Epi-dihydrotestosterone		3	B	Testosterone Link - androgenic metabolite of testosterone.	Metabolite of a B substance
Epibatidine		2	A		
Epinephrine		2	A		
Epi-testosterone		3	B	Testosterone Link - endogenous steroid and an epimer of the androgen sex hormone testosterone.	Endogenous, stereoisomer of a B substance.
EPO-Fc		1	A	Erythropoietin Link - fusion protein in human blood	Blood doping agent
EPO-mimetic peptides (EMP):		1	A		
Ergoloid mesylates (dihydroergocornine mesylate, dihydroergocristine mesylate, and dihydroergocryptine mesylate)		2	A		
Ergonovine	<i>Ergotrate</i>	4	C		
Ergotamine	<i>Gynergen, Cafergot, etc.</i>	4	B		
Erthrityl tetranitrate	<i>Cardilate</i>	3	A		

Erythropoietin (EPO)	<i>Epogen, Procrit, etc.</i>	1	A		
Esmolol	<i>Brevibloc</i>	3	B		

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
Esomeprazole	<i>Nexium</i>	5	D		
Estazolam	<i>Domnamid, Eurodin, Nuctalon</i>	2	A		
Eszopiclone		2	A		
Etacrynic acid		3	C		
Etamiphylline		3	B		
Etanercept	<i>Enbrel</i>	4	B		
Ethacrynic acid	<i>Edecrin</i>	3	B		
Ethamivan		2	A		
Ethanol		2	A		
Ethchlorvynol	<i>Placidyl</i>	2	A		
Ethinamate	<i>Valmid</i>	2	A		
Ethoheptazine	<i>Zactane</i>	2	A		
Ethopropazine	<i>Parsidol</i>	2	A		
Ethosuximide	<i>Zarontin</i>	3	A		
Ethotoin	<i>Peganone</i>	4	B		
Ethoxzolamide	<i>Cardrase, Ethamide</i>	4	C		
Ethylaminobenzoate (Benzocaine)	<i>Semets, etc.</i>	4	C		
Ethylestrenol	<i>Maxibolin, Organon</i>	3	B		

Ethylisobutrazine	<i>Diquel</i>	2	A		
Ethylmorphine	<i>Dionin</i>	1	A		
Ethylnorepinephrine	<i>Bronkephrine</i>	3	A		
Ethylphenidate		1	A		

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
Etidocaine	<i>Duranest</i>	2	A		
Etifoxin	<i>Stresam</i>	2	A		
Etiocanolone		3	B	Testosterone Link - etiocholane steroid as well as an endogenous 17-ketosteroid that is produced from the metabolism of testosterone.	Metabolite of a B substance
Etizolam	<i>Depas, Pasaden</i>	2	A		
Ethamsylate		4	B		
Etodolac	<i>Lodine</i>	3	B		
Etodroxizine	<i>Indunox</i>	2	A		
Etofenamate		4	B	Consistent with other non-FDA approved NSAIDs	
Etomidate		2	A		
Etorphine HCl	<i>M99</i>	1	A		
Exemestane	Aromatase inhibitors	3	B	Hormone and Metabolic effects, same classification as Testolactone on Human Olympic Guidelines - Aromatase inhibitors	Testolactone has B classification
Famotidine	<i>Gaster, etc.</i>	5	D		
Felbamate	<i>Felbatol</i>	3	B		

Felodipine	<i>Plendil</i>	4	B		
Fenarbamate	<i>Tymium</i>	2	A		
Fenbufen	<i>Cincopal</i>	3	B		
Fenclozic acid	<i>Myalex</i>	2	B		
Fenfluramine	<i>Pondimin</i>	2	A		
Fenoldopam	<i>Corlopam</i>	3	B		
Fenopropfen	<i>Nalfon</i>	3	B		

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
Fenoterol	<i>Berotec</i>	3	B		
Fenspiride	<i>Respiride, Respan, etc</i>	3	B		
Fentanyl	<i>Sublimaze</i>	1	A		
Fentiazac		3	B		
Fexofenadine	<i>Allegra</i>	4	C		

Fibroblast Growth Factors (fgfs), Hepatocyte Growth Factor (HGF), Insulin-like Growth Factor-1 (IGF-1) and its analogues, Mechano Growth Factors (mgfs), Platelet-Derived Growth Factor (PDGF), Vascular-Endothelial Growth Factor (VEGF) and any other growth factor affecting muscle, tendon or ligament protein synthesis/degradation, vascularization, energy utilization, regenerative capacity or fiber type switching.		3	A	Cardiac, Muscle effects - a family of peptide cytokines that are important in the regulation of many tissues.	Lack FDA approval; no legitimate use in race horse.
Firocoxib		4	C		
Flecainide	<i>Idalon</i>	4	B		
Floctafenine	<i>Idalon, Idarac</i>	4	B		
Fluanisone	<i>Sedalande</i>	2	A		
Fludiazepam	<i>Erispam</i>	2	A		
Fludrocortisone	<i>Alforone, etc.</i>	4	C		
Flufenamic acid		4	B		

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
Flumethasone	<i>Flucort, etc.</i>	4	C		
Flumethiazide	<i>Ademol</i>	4	B		

Flunarizine	<i>Sibelium</i>	4	B		
Flunisolide	<i>Bronilide, etc.</i>	4	C		
Flunitrazepam	<i>Rohypnol, Narcozep, Darkene, Hypnodorm</i>	2	A		
Flunixin	<i>Banamne</i>	4	C*		
Fluocinolone	<i>Synalar</i>	4	C		
Fluocinonide	<i>Licon, Lidex</i>	4	C		
Fluopromazine	<i>Psyquil, Siquil</i>	2	A		
Fluoresone	<i>Caducid</i>	2	A		
Fluorometholone	<i>FML</i>	4	C		
Fluoroprednisolone		4	B		
Fluoxetine	<i>Prozac</i>	2	A		
Fluoxymesterone	<i>Halotestin</i>	3	B		
Flupenthixol	<i>Depixol, Fluanxol</i>	2	A		
Fluphenazine	<i>Prolixin, Permitil, Anatsol, etc.</i>	2	B		
Flupirtine	<i>Katadolone</i>	3	A		
Fluprednisolone	<i>Alphadrol</i>	4	C		
Flurandrenolide	<i>Cordran</i>	4	C		
Flurazepam	<i>Dalmane</i>	2	A		
Flurbiprofen	<i>Froben</i>	3	B		
Fluspirilene	<i>Imap, Redeptin</i>	2	A		

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
Fluticasone	<i>Flixonase, Flutide</i>	4	C		
Flutoprazepam	<i>Restas</i>	2	A		
Fluvoxamine	<i>Dumirox, Faverin, etc.</i>	2	A		
Formebolone		3	A		
Formestane	Aromatase inhibitors	3	B	Hormone and Metabolic effects, same classification as Testolactone on Human Olympic Guidelines - Aromatase inhibitors.	Testolactone has B classification
Formoterol	<i>Altram</i>	3	B		
Fosinopril	<i>Monopril</i>	3	A		
Fosphenytoin	<i>Cerebyx</i>	3	B		
Fulvestrant		3	B	Hormone and Metabolic effects, same classification as Testolactone on Human Olympic Guidelines - Estrogen receptor antagonist antineoplastic agent.	Testolactone has B classification
Furazabol		3	A		
Furosemide	<i>Lasix</i>	N/A			
Gabapentin	<i>Neurontin</i>	3	B		
Galantamine	<i>Reminyl</i>	2	A		
Gallamine	<i>Flaxedil</i>	2	A		
Gamma Aminobutyric Acid (GABA)	<i>Carolina Gold</i>	3	B		
Gepirone		2	A		
Gestrinone		3	A		

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
GH-Releasing Peptides (ghrps), e.g., alexamorelin, GHRP-6, hexarelin and pralmorelin (GHRP-2)		3	A	Anabolic Effects - a synthetic GH secretagogue.	Anabolic agent lacking FDA approval
Glutethimide	<i>Doriden</i>	2	A		
Glycopyrrolate	<i>Robinul</i>	4	C		
Growth Hormone Releasing Hormone (GHRH) and its analogues, e.g., CJC-1295, sermorelin and tesamorelin		3	A	Anabolic Effects - peptide analogue of growth hormone-releasing hormone which is used as a diagnostic agent to assess growth hormone secretion for the purpose of diagnosing growth hormone deficiency.	Anabolic agent lacking FDA approval
Growth Hormone Secretagogues (GHS), e.g., ghrelin and ghrelin mimetics, e.g., anamorelin and ipamorelin		3	A	Anabolic Effects - hunger hormone, appetiteenhancing and anabolic effects.	Anabolic agent lacking FDA approval
Guaifenesin (glycerol guaiacolate)	<i>Gecolate</i>	4	C		
Guanabenz	<i>Wytensin</i>	3	B		
Guanadrel	<i>Hylorel</i>	3	A		
Guanethidine	<i>Ismelin</i>	3	A		
Halazepam	<i>Paxipam</i>	2	A		
Halcinonide	<i>Halog</i>	4	C		
Halobetasol	<i>Ultravate</i>	4	C		

Haloperidol	<i>Haldol</i>	2	A		
Haloxazolam	<i>Somelin</i>	2	A		
Harpagoside		4	B	Devil's Claw Plant	

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note
Hemoglobin glutamers	<i>Oxyglobin Hemopure</i>	2	A		
Heptaminol	<i>Corofundol</i>	3	B		
Heroin		1	A		
Hexafluorenum	<i>Myalexen</i>	2	A		
Hexobarbital	<i>Evipal</i>	2	A		
Hexocyclium	<i>Tral</i>	4	B		
Hexylcaine	<i>Cyclaine</i>	2	B		
HIF activators (e.g. Argon, xenon)		3	A	Cardiovascular Effects - a key mediator of oxygen homeostasis that was first identified as a transcription factor that is induced and activated by decreased oxygen tension.	Blood doping agent
Homatropine	<i>Homapin</i>	3	B		
Homophenazine	<i>Pelvichthol</i>	2	A		
Hydralazine	<i>Apresoline</i>	3	B		
Hydrochlorothiazide	<i>Hydrodiuril</i>	4	B		
Hydrocodone (dihydrocodienone)	<i>Hycodan</i>	1	A		
Hydrocortisone (Cortisol)	<i>Cortef, etc.</i>	4	C		

Hydroflumethiazide	<i>Sahuron</i>	4	B		
Hydromorphone	<i>Dilaudid</i>	1	A		
Hydroxyamphetamine	<i>Paradrine</i>	1	A		
Hydroxyzine	<i>Atarax</i>	2	B		
Hypoxia-inducible factor (HIF) activators		1	A	Blood doping agent	
Hypoxia-inducible factor (HIF) stabilizers (e.g. IOX-2)		1	A	Blood doping agent	
Ibomal	<i>Noctal</i>	2	A		

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
Ibuprofen	<i>Motrin, Advil, Nurpin, etc.</i>	4	C		
Ibutilide	<i>Corvert</i>	3	B		
Iloprost	<i>Ventavis</i>	3	A		
Imipramine	<i>Imavate, Presamine, Tofranil</i>	2	A		
Indapamide	Diuretic	3	C		
Indomethacin	<i>Indocin</i>	3	B		
Infliximab	<i>Remicade</i>	4	B		
Insulins		3	B	Hormone and Metabolic effects, same classification as Testolactone on Human Olympic Guidelines - protein hormone that is used as a medication to treat high blood sugar.	
Ipratropium		3	B		
Irbesarten	<i>Avapro</i>	3	A		
Isapirone		2	A		
Isocarboxazid	<i>Marplan</i>	2	A		
Isoetharine	<i>Bronkosol</i>	3	B		

Isoflupredone	<i>Predef 2x</i>	4	C		
Isomethadone		2	A		
Isometheptene	<i>Octin, Octon</i>	4	B		
Isopropamide	<i>Darbid</i>	4	B		
Isoproterenol	<i>Isoprel</i>	2	A		
Isosorbide dinitrate	<i>Isordil</i>	3	B		
Isoxicam	<i>Maxicam</i>	2	B		
Isoxsuprine	<i>Vasodilan</i>	4	D		
Isradipine	<i>DynaCirc</i>	4	B		

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
Kebuzone		3	B		
Ketamine	<i>Ketalar, Ketaset, Vetalar</i>	2	B		
Ketazolam	<i>Anxon, Lafram, Solatran, Lofiran</i>	2	A		
Ketoprofen	<i>Orudis</i>	4	C*		
Ketorolac	<i>Toradol</i>	3	A		
Labetalol	<i>Normodyne</i>	3	B		
Lamotrigine	<i>Lamictal</i>	3	A		
Lansoprazole		5	D		
Lenperone	<i>Elanone-V</i>	2	A		
Letosteine	<i>Viscotiol, Visiotol</i>	4	B		
Letrozole		3	A		

Levamisole		2	B		
Levobunolol	<i>Betagan</i>	3	B		
Levomethorphan		2	A		
Levorphanol	<i>Levo-Dremoran</i>	1	A		
Lidocaine	<i>Xylocaine</i>	2	B		
Ligandrol		2	A		SARM
Lisinopril	<i>Prinivil, Zestril</i>	3	A		
Lithium	<i>Lithizine, Duralith, etc</i>	2	A		
Lobeline		2	A		
Lofentanil		1	A		
Loflazepate, Ethyl	<i>Victan</i>	2	A		

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note
Loperamide	<i>Imodium</i>	3	B		
Loprazolam	<i>Dormonort, Havlane</i>	2	A		
Loratidine	<i>Claritin</i>	4	C		
Lorazepam	<i>Ativan</i>	2	A		
Lormetazepam	<i>Noctamid</i>	2	A		
Losartan	<i>Hyzaar</i>	3	B		
Loxapine	<i>Laxitane</i>	2	A		
Luteinizing Hormone (LH)		3	B		Hormone and behavioral effects - a hormone produced by gonadotropic cells in the anterior pituitary gland. In females, an acute rise of LH triggers ovulation and development of the corpus luteum. Used for behavior modification in colts / horses. There should be no restriction/regulation in fillies and mares.

Mabuterol		3	A		
Maprotiline	<i>Ludiomil</i>	2	A		
Mazindol	<i>Sanorex</i>	1	A		
Mebutamate	<i>Axiten, Dormate, Capla</i>	2	A		
Mecamylamine	<i>Inversine</i>	3	B		
Meclizine	<i>Antivert, Bonine</i>	3	B		
Meclofenamic acid	<i>Arquel</i>	4	C		
Meclofenoxate	<i>Lucidril, etc.</i>	2	A		
Medazepam	<i>Nobrium, etc.</i>	2	A		
Medetomidine	<i>Damintor</i>	3	B		
Medroxyprogesterone		3	B	Classification for all genders	
Medrysone	<i>Medrusar, etc.</i>	4	C		
Mefenamic acid	<i>Ponstel</i>	3	B		

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
Meldonium	<i>Mildronate, et al</i>	1	A		
Meloxicam	<i>Mobic</i>	4	B		
Melperone	<i>Eunerpan</i>	2	A		
Memantine	<i>Namenda</i>	2	A		
Meparfynol	<i>Oblivon</i>	2	A		
Mepazine	<i>Pacatal</i>	2	A		
Mepenzolate	<i>Cantil</i>	3	B		

Meperidine	<i>Demerol</i>	1	A		
Mephesisin	<i>Tolserol</i>	4	B		
Mephenoqualone	<i>Control, etc.</i>	2	A		
Mephentermine	<i>Wyamine</i>	1	A		
Mephentyoin	<i>Mesantoin</i>	2	A		
Mephobarbital (Methylphenobarbital)	<i>Meharal</i>	2	A		
Mepivacaine	<i>Carbocaine</i>	2	B		
Meprobamate	<i>Equanil, Miltown</i>	2	A		
Meralluride	<i>Mercurhydrin</i>	4	B		
Merbaphen	<i>Novasural</i>	4	B		
Mercaptomerin	<i>Thiomerin</i>	4	B		
Mercumatilin	<i>Cumertilin</i>	4	B		
Mersalyl	<i>Salyrgan</i>	4	B		
Mesalamine	<i>Asacol</i>	5	C		
Mesoridazine	<i>Serentil</i>	2	A		

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
Mestanolone		3	A		
Mesterolone		3	A		
Metaclozepam	<i>Talis</i>	2	A		
Metandienone		3	A	Steroid	AAS lacking FDA approval
Metaproterenol	<i>Alupent, Metaprel</i>	3	B		

Metaraminol	<i>Aramine</i>	1	A		
Metaxalone	<i>Skelaxin</i>	4	B		
Metazocine		2	A		
Metenolone		3	A	Steroid	AAS lacking FDA approval
Metformin		2	B		
Methacholine		3	A		
Methadone	<i>Dolophine</i>	1	A		
Methamphetamine	<i>Desoxyn</i>	1	A4	Recommended Penalty B if testing can prove presence of only levo-methamphetamine is present in sample	
Methandriol (Methylandrostenediol)	<i>Probolis</i>	3	A		
Methandrostenolone	<i>Dianabol</i>	3	A		
Methantheline	<i>Banthine</i>	3	B		
Methapyrilene	<i>Histadyl, etc.</i>	3	B		
Methaqualone	<i>Quaalude</i>	1	A		
Metharbital	<i>Gemonil</i>	2	A		
Methasterone		3	A		
Methazolamide	<i>Naptazane</i>	4	C		
Methcathinone		1	A		

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
Methdilazine	<i>Tacaryl</i>	3	B		
Methenolone	<i>Primobolan</i>	3	A		
Methixene	<i>Trest</i>	3	A		

Methocarbamol	<i>Robaxin</i>	4	C		
Methohexital	<i>Brevital</i>	2	A		
Methotrexate	<i>Folex, Nexate, etc.</i>	4	B		
Methotrimeprazine	<i>Levoprome, Neurocil, etc.</i>	2	A		
Methoxamine	<i>Vasoxyl</i>	3	A		
Methoxyphenamine	<i>Orthoxide</i>	3	A		
Methoxypolyethylene glycol-epoetin beta (CERA)		1	A	Erythropoietin Link - an erythropoiesis-stimulating agent (ESA) indicated for the treatment of anemia associated with chronic kidney disease (CKD) in adult patients on dialysis and patients not on dialysis.	Blood doping agent
Methscopolamine	<i>Pamine</i>	4	B		
Methsuximide	<i>Celontin</i>	4	B		
Methyclothiazide	<i>Enduron</i>	4	B		
Methyl-1-testosterone		3	A		
Methylatropine		3	B		
Methyldienolone		3	A		
Methyldopa	<i>Aldomet</i>	3	A		
Methylergonovine	<i>Methergine</i>	4	C		
Methylhexanamine (Methylhexanamine)	<i>Geranamine</i>	1	A		

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note
Methylnortestosterone (Trestolone)		3	A		

Methylphenidate	<i>Ritalin</i>	1	A		
Methylprednisolone	<i>Medrol</i>	4	C		
Methyltestosterone	<i>Metandren</i>	3	B		
Methypylon	<i>Noludar</i>	2	A		
Methysergide	<i>Sansert</i>	4	B		
Metiamide		4	B		
Metoclopramide	<i>Reglan</i>	4	C		
Metocurine	<i>Metubine</i>	2	A		
Metolazone		3	B		
Metomidate	<i>Hypnodil</i>	2	A		
Metopon (methyldihydromorphin one)		1	A		
Metoprolol	<i>Lopressor</i>	3	B		
Metribolone		3	A	Steroid	AAS lacking FDA approval
Mexazolam	<i>Melex</i>	2	A		
Mexiletine	<i>Mexitil</i>	4	B		
Mibefradil	<i>Posicor</i>	3	B		
Mibolerone		3	B		
Midazolam	<i>Versed</i>	3	B		
Midodrine	<i>Pro-Amiline</i>	3	B		
Milrinone		4	B		

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
Minoxidil	<i>Loniten</i>	3	B		
Mirtazepine	<i>Remeron</i>	2	A		
Misoprostol	<i>Cytotec</i>	5	D		
Mitragynine	<i>Kratom</i>	1	A		
Mivacurium	<i>Mivacron</i>	2	A		
Modafinil	<i>Provigil</i>	2	A		
Moexipril (metabolite, moexiprilat)	<i>Uniretic</i>	3	B		
Molidustat		1	A	Blood doping agent	
Molindone	<i>Moban</i>	2	A		
Mometasone	<i>Elocon</i>	4	C		
Montelukast	<i>Singulair</i>	4	C		
Moperone	<i>Luvatren</i>	2	A		
Morphine		1	A6	If it is determined by the State Veterinarian/Equine Medical Director, the Stewards, or the Racing Authority that the finding of cocaine or morphine was unintentional and not based upon an attempt to affect the outcome of a race, the Stewards or Racing Authority may elect to assign a Class B penalty to the trainer.	
Mosaprimine		2	A		
Muscarine		3	A		
myo-inositol trispyrophosphate (ITPP)		1	A		
N-Butylscopolamine		4	C		
Nabumetone	<i>Anthraxan, Relafen, Reliflex</i>	3	A		

Nadol	<i>Corgard</i>	3	B		
Naepaine	<i>Amylsine</i>	2	A		
Nalbuphine	<i>Nubain</i>	2	A		

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
Nalorphine	<i>Nalline, Lethidrone</i>	2	A		
Naloxone	<i>Narcan</i>	3	B		
Naltrexone	<i>Revia</i>	3	B		
Nandrolone	<i>Nandrolin, Laurabolin, Durabolin</i>	3	B		
Naphazoline	<i>Privine</i>	4	B		
Naproxen	<i>Equiproxen, Naprosyn</i>	4	C		
Naratriptan	<i>Amerge</i>	3	B		
Nebivolol		3	A		
Nedocromil	<i>Tilade</i>	5	D		
Nefazodone	<i>Serzone</i>	2	A		
Nefopam		3	A		
Neostigmine	<i>Prostigmine</i>	3	B		
Nicardipine	<i>Cardine</i>	4	B		
Nifedipine	<i>Procardia</i>	4	B		
Niflumic acid	<i>Nifluril</i>	3	B		
Nikethamide	<i>Coramine</i>	1	A		

Nimesulide		3	B		
Nimetazepam	<i>Erimin</i>	2	A		
Nimodipine	<i>Nemotop</i>	4	B		
Nitrazepam	<i>Mogadon</i>	2	A		
Nitroglycerin		2	B		
Nizatidine	<i>Axid</i>	5	D		

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
<i>Norandrosterone</i>		3	B	Nandrolone Link - a detectable metabolite of nandrolone, an anabolic-androgenic steroid.	Metabolite of a B substance
Norbolethone/Norboletone		3	A		
Norclostebol		3	A		
Nordiazepam	<i>Calmday, Nordaz, etc.</i>	2	A		
Norethisterone (norethindrone)		4	B all genders	No known use in the horse	
Norepinephrine		2	A		
Norethandrolone		3	A		
Nortestosterone		3	B		
Nortriptyline	<i>Aventyl, Pamelor</i>	2	A		
Nylidrine	<i>Arlidin</i>	3	A		
Olanzapine	<i>Zyprexa</i>	2	A		
Oliceridine		1	A	FDA approved opioid for humans	
Olmesartan	<i>Benicar</i>	3	A		

Version 14.4, December 2020

Olsalazine	<i>Dipentum</i>	5	C		
Omeprazole	<i>Prilosec, Losec</i>	5	D		
Oripavine		2	A		
Orphenadrine	<i>Norlfex</i>	4	B		
Ostarine		2	A		SARM
Oxabolone		3	A		
Oxandrolone	<i>Anavar</i>	3	B		
Oxaprozin	<i>Daypro, Deflam</i>	4	B		
Oxazepam	<i>Serax</i>	2	A		
Oxazolam	<i>Serenal</i>	2	A		
Oxcarbazepine	<i>Trileptal</i>	3	A		

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
Oxilofrine (hydroxyephedrine)		2	A		
Oxprenolol	<i>Trasicor</i>	3	A		
Oxycodone	<i>Percodan</i>	1	A		
Oxymesterone		3	A		
Oxymetazoline	<i>Afrin</i>	4	B		
Oxymetholone	<i>Adroyd, Anadrol</i>	3	B		
Oxymorphone	<i>Numorphan</i>	1	A		
Oxyperitine	<i>Forit, Integrin</i>	2	A		

Oxyphenbutazone	<i>Tandearil</i>	4	C		
Oxyphencyclimine	<i>Daricon</i>	4	B		
Oxyphenonium	<i>Antrenyl</i>	4	B		
Paliperidone		2	A		
Pancuronium	<i>Pavulon</i>	2	A		
Pantoprazole	<i>Protonix</i>	5	D		
Papaverine	<i>Pavagen, etc.</i>	3	A		
Parecoxib		4	B		
Paraldehyde	<i>Paral</i>	2	A		
Paramethadione	<i>Paradione</i>	3	A		
Paramethasone	<i>Haldrone</i>	4	C		
Pargyline	<i>Eutonyl</i>	3	A		
Paroxetine	<i>Paxil, Seroxat</i>	2	A		

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
Peginesatide		1	A	Erythropoietin Link - an erythropoiesis-stimulating agent (ESA) indicated for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis.	Blood doping agent
Pemoline	<i>Cylert</i>	1	A		
Penbutolol	<i>Levatol</i>	3	B		
Penfluridol	<i>Cyperon</i>	2	A		

Pentaerythritol tetranitrate	<i>Duotrate</i>	3	A		
Pentazocine	<i>Talwin</i>	3	B		
Pentobarbital	<i>Nembutal</i>	2	A		
Pentoxyfylline	<i>Trental, Vazofirin</i>	4	D		
Pentylene tetrazol	<i>Metrazol, Nioric</i>	1	A		
Perazine	<i>Taxilan</i>	2	A		
Perfluorocarbons		2	A		
Perfluorodecahydronaphthalene		2	A		
Perfluorodecolin		2	A		
Perfluorooctylbromide		2	A		
Perfluorotripropylamine		2	A		
Pergolide	<i>Permax</i>	3	B		
Periciazine	<i>Alodept, etc.</i>	2	A		
Perindopril	<i>Biprel</i>	3	A		
Perlapine	<i>Hypnodin</i>	2	A		

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
Perphenazine	<i>Trilafon</i>	2	A		
Phenacemide	<i>Phenurone</i>	4	B		
Phenaglycodol	<i>Acalo, Alcamid, etc.</i>	2	A		
Phenazocine	<i>Narphen</i>	1	A		

Phencyclidine (PCP)	<i>Sernylan</i>	1	A		
Phendimetrazine	<i>Bontril, etc</i>	1	A		
Phenelzine	<i>Nardelzine, Nardil</i>	2	A		
Phenindione	<i>Hedulin</i>	5	D		
Phenmetrazine	<i>Preludin</i>	1	A		
Phenobarbital	<i>Luminal</i>	2	A		
Phenoxybenzamine	<i>Dibenzyline</i>	3	B		
Phenprocoumon	<i>Liquamar</i>	5	D		
Phensuximide	<i>Milontin</i>	4	B		
Phentermine	<i>Iomamin</i>	2	A		
Phentolamine	<i>Regitine</i>	3	B		
Phenylbutazone	<i>Butazolidin</i>	4	C*		
Phenylephrine	<i>Isophrin, Neo-Synephrine</i>	3	B		
Phenylpropanolamine	<i>Propadrine</i>	3	B		
Phenytoin	<i>Dilantin</i>	4	B		
Physostigmine	<i>Eserine</i>	3	A		
Picrotoxin		1	A		
Piminodine	<i>Alvodine, Cimadon</i>	2	A		

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note
Pimobendan		2	B		
Pimozide	<i>Orap</i>	2	A		
Pinazepam	<i>Domar</i>	2	A		
Pindolol	<i>Viskin</i>	3	B		
Pipamperone	<i>Dipiperon</i>	2	A		
Pipecuronium	<i>Arduan</i>	2	A		
Pipecqualine		2	A		
Piperacetazine	<i>Psymod, Quide</i>	2	A		
Piperocaine	<i>Metycaine</i>	2	A		
Pipotiazine	<i>Lonseren, Piportil</i>	2	A		
Pipradrol	<i>Dataril, Gerondyl, etc.</i>	2	A		
Piquindone		2	A		
Pirbuterol	<i>Maxair</i>	3	B		
Pirenzepine	<i>Gastrozepin</i>	5	C		
Piretanide	<i>Arelis, Tauliz</i>	3	B		
Piritramide		1	A		
Piroxicam	<i>Feldene</i>	4	B		

Plasma expanders (e.g. Bycerol; intravenous administration of albumin, dextran, hydroxyethyl starch and mannitol)		3	A	No legit use in the racehorse. Lacks FDA approval.	
Polyethylene glycol		5	D		
Polythiazide	<i>Renese</i>	4	B		

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
Pramoxine	<i>Tronothaine</i>	4	C		
Prasterone (dehydroepiandrosterone, DHEA, 3 β hydroxyandrost-5-en17-one)		3	B	Steroid - inactive endogenous steroid.	Endogenous AAS
Prazepam	<i>Vertran, Centrax</i>	2	A		
Prazosin	<i>Mimipress</i>	3	B		
Prednisolone	<i>Delta-Cortef, etc.</i>	4	C		
Prednisone	<i>Meticorten, etc.</i>	4	C		
Pregabalin	<i>Lyrica</i>	3	B	Gabapentanoid	
Prilocaine	<i>Citanest</i>	2	B		
Primidone	<i>Mysoline</i>	3	B		
Probenecid		4	C		
Procainamide	<i>Pronestyl</i>	4	B		
Procaine		3	B		

Procaterol	<i>Pro Air</i>	3	A		
Prochlorperazine	<i>Darbazine, Compazine</i>	2	A		
Procyclidine	<i>Kemadrin</i>	3	B		
Promazine	<i>Sparine</i>	3	B		
Promethazine	<i>Phenergan</i>	3	B		
Propafenone	<i>Rythmol</i>	4	B		
Propanidid		2	A		
Propantheline	<i>Pro-Banthine</i>	3	B		
Proparacaine	<i>Ophthaine</i>	4	C		

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
Propentophylline	<i>Karsivan</i>	3	B		
Propiomazine	<i>Largon</i>	2	A		
Propionylpromazine	<i>Tranvet</i>	2	A		
Propiram		2	A		
Propofol	<i>Diprivan, Disoprivan</i>	2	A		
Propoxycaine	<i>Ravocaine</i>	2	A		
Propranolol	<i>Inderal</i>	3	B		
Propylhexedrine	<i>Benzedrex</i>	4	B		
Prostanazol		3	A		

Prothipendyl	<i>Dominal</i>	2	A		
Protokylol	<i>Ventaire</i>	3	A		
Protriptyline	<i>Concordin, Triptil</i>	2	A		
Proxibarbital	<i>Axeen, Centralgol</i>	2	A		
Pseudoephedrine	<i>Cenafed, Novafed</i>	3	B		
Pyridostigmine	<i>Mestinon, Regonol</i>	3	B		
Pyrilamine	<i>Neoantergan, Equihist</i>	3	B		
Pyrithyldione	<i>Hybersulfan, Sonodor</i>	2	A		
Quazipam	<i>Doral</i>	2	A		
Quetiapine	<i>Seroquel</i>	2	A		
Quinapril, Quinaprilat	<i>Accupril</i>	3	A		
Quinbolone		3	A		
Quinidine	<i>Quinidex, Quinocardine</i>	4	B		

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
Rabeprazole	<i>Aciphex</i>	5	D		
Racemethorphan		2	A		
Racemorphan		2	A		
Raclopride		2	A		
Ractopamine	<i>Paylean</i>	2	A		

Raloxifene		3	B	Estrogen effects, same classification as Testolactone on Human Olympic Guidelines - selective estrogen receptor modulators-SERMs.	Testolactone has B classification
Ramipril, metabolite Ramiprilat	<i>Altace</i>	3	A		
Ranitidine	<i>Zantac</i>	5	D		
Remifentanyl	<i>Ultiva</i>	1	A		
Remoxipride	<i>Roxiam</i>	2	A		
Reserpine	<i>Serpasil</i>	2	B		
Rilmazafone		2	A		
Risperidone		2	A		
Ritanserlin		2	A		
Ritodrine	<i>Yutopar</i>	3	B		
Rivastigmine	<i>Exelon</i>	2	A		
Rizatriptan	<i>Maxalt</i>	3	B		
Rocuronium	<i>Zemuron</i>	2	A		
Rofecoxib	<i>Vioxx</i>	2	B		
Romifidine	<i>Sedivet</i>	3	B		

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
Ropivacaine	<i>Naropin</i>	2	A		

Roxadustat (FG-4592)		1	A	Erythropoietin Link - HIF prolyl-hydroxylase inhibitor and thereby increases endogenous production of erythropoietin, which stimulates production of hemoglobin and red blood cells.	Blood doping agent
Salicylamide		4	C		
Salicylate		4	C		
Salmeterol		3	B		
Scopolamine (Hyoscine)	<i>Triptone</i>	4	C		
Secobarbital (Quinalbarbitone)	<i>Seconal</i>	2	A		
Selective Androgen Receptor Modulators (SARMs)		2	A		
Selegiline	<i>Eldepryl, Jumex, etc</i>	2	A		
Sertraline	<i>Lustral, Zoloft</i>	2	A		
Sibutramine	<i>Meridia</i>	3	B		
Sildenafil	<i>Viagra</i>	3	A		
Snake Venoms		1	A		
Somatrem	<i>Protropin</i>	2	A		
Somatropin	<i>Nutropin</i>	2	A		
Sotalol	<i>Betapace, Sotacor</i>	3	B		
Spiclomazine		2	A		
Spiperone		2	A		

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
----------------	---------------	------------	---------------	------------------	-------

Spirapril, metabolite Spiraprilat	<i>Renomax</i>	3	A		
Spironalactone	<i>Aldactone</i>	4	B		
Spironolactone	Diuretic	3	C		
Stanozolol	<i>Winstrol-V</i>	3	B		
Stenbolone		3	A		
Strychnine		1	A		
Succinylcholine	<i>Sucostrin, Quelin, etc.</i>	2	A		
Sufentanil	<i>Sufenta</i>	1	A		
Sulfasalazine	<i>Azulfidine, Azaline</i>	4	C		
Sulfondiethylmethane		2	A		
Sulfonmethane		2	A		
Sulforidazine	<i>Inofal</i>	2	A		
Sulindac	<i>Clinoril</i>	3	B		
Sulpiride	<i>Aiglonyl, Sulpitil</i>	2	A		
Sultopride	<i>Barnetil</i>	2	A		
Sumatriptan	<i>Imitrex</i>	3	B		
Synthetic cannabis	<i>Spice, K2, Kronic</i>	1	A		
Tadalafil	<i>Cialis</i>	3	A		
Talbutal	<i>Lotusate</i>	2	A		
Tamoxifen		3	B	Hormone and Metabolic effects, same classification as Testolactone on Human Olympic Guidelines - Estrogen receptor antagonist antineoplastic agent.	Testolactone has B classification

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
Tandospirone		2	A		
Tapentadol	<i>Nucynta</i>	1	A		
TCO2		3	B		
Telmisartan	<i>Micardis</i>	3	B		
Temazepam	<i>Restoril</i>	2	A		
Tenoxicam	<i>Alganex, etc.</i>	3	B		
Tepoxalin		3	B		
Terazosin	<i>Hytrin</i>	3	A		
Terbutaline	<i>Brethine, Bricanyl</i>	3	B		
Terfenadine	<i>Seldane, Trihudan</i>	4	C		
Testolactone	<i>Teslac</i>	3	B		
Testolone		2	A		SARM
Testosterone		3	B		
Tetrabenazine	<i>Nitoman</i>	2	A		
Tetracaine	<i>Pontocaine</i>	2	A		
Tetrahydrogestrinone		3	A		
Tetrahydrozoline	<i>Tyzine</i>	4	B		
Tetrazepam	<i>Musaril, Myolastin</i>	2	A		
THC (tetrahydrocannabinol) ²	Drug of human abuse	1	A	Drug of human abuse	
Thebaine		2	A		
Theobromine		4	B		

Theophylline	<i>Aqualphyllin, etc.</i>	3	B		
Thialbarbital	<i>Kemithal</i>	2	A		

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
Thiamylal	<i>Surital</i>	2	A		
Thiethylperazine	<i>Torecan</i>	2	A		
Thiopental	<i>Pentothal</i>	2	A		
Thiopropazate	<i>Dartal</i>	2	A		
Thiopropazine	<i>Majeptil</i>	2	A		
Thioridazine	<i>Mellaril</i>	2	A		
Thiosalicylate		4	B		
Thiothixene	<i>Navane</i>	2	A		
Thiphenamil	<i>Trocinate</i>	4	B		
Thyroxine and thyroid modulators/hormones, including but not limited to those containing T4 (tetraiodothyronine/thyroxine), T3 (triiodothyronine), or combinations thereof.	Levothyroxine	3	C	FDA approved but has (limited) legitimate use in care of racehorses.	
Tiaprside	<i>Italprid, Lucoben, etc.</i>	2	A		
Tiaprofenic acid	<i>Surgam</i>	3	B		
Tibolone		3	A	Steroid - synthetic steroid.	AAS lacking FDA approval
Tildronate Sodium	<i>Tildren</i>	3	A	Bisphosphonate	
Tiletamine	<i>Component of Telazol</i>	2	A		

Timiperone	<i>Tolopelon</i>	2	A		
Timolol	<i>Blocadrin</i>	3	B		
Tocainide	<i>Tonocard</i>	4	B		
Tofisopam	<i>Grandaxin, Seriel</i>	2	A		

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
Tolazoline	<i>Priscoline</i>	3	B		
Tolfenamic Acid		4	B		
Tolmetin	<i>Tolectin</i>	3	B		
Topirimate	<i>Topamax</i>	2	A		
Toremifene		3	B	Hormone and Metabolic effects, same classification as Testolactone on Human Olympic Guidelines - Selective estrogen receptor modulator.	
Torsemide (Torasemide)	<i>Demadex</i>	3	A		
Tramadol	<i>Ultram</i>	2	B		
Trandolapril (and metabolite, trandolaprilat)	<i>Tarka</i>	3	B		
Tranexamic acid		4	C		
Tranylcypromine	<i>Parnate</i>	2	A		
Trazodone	<i>Desyrel</i>	2	A		
Trenbolone	<i>Finoplif</i>	3	B		
Tretoquinol	<i>Inolin</i>	2	A		
Triamcinolone	<i>Vetalog, etc.</i>	4	C		
Triamterene	<i>Dyrenium</i>	4	B		
Triazolam	<i>Halcion</i>	2	A		

Tribromethanol		2	A		
Tricaine methanesulfonate	<i>Finquel</i>	2	A		
Trichlormethiazide	<i>Naqua, Naquasone</i>	4	C		
Trichloroethanol		2	A		
Trichloroethylene	<i>Trilene, Trimar</i>	2	A		

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
Triclofos	<i>Triclos</i>	2	A		
Tridihexethyl	<i>Pathilon</i>	4	B		
Trifluomeprazine	<i>Nortran</i>	2	A		
Trifluoperazine	<i>Stelazine</i>	2	A		
Trifluoperidol	<i>Triperidol</i>	2	A		
Triflupromazine	<i>Yetame, Yesprin</i>	2	A		
Trihexylphenidyl	<i>Artane</i>	3	A		
Trimeprazine	<i>Temaril</i>	4	B		
Trimetazidine		3	B	Hormone and Metabolic effects, same classification as Testolactone on Human Olympic Guidelines - a drug for angina pectoris, the first cytoprotective anti- ischemic agent.	
Trimethadione	<i>Tridione</i>	3	B		
Trimethaphan	<i>Arfonad</i>	3	A		
Trimipramine	<i>Surmontil</i>	2	A		
Tripelennamine	<i>PBZ</i>	3	B		
Triprolidine	<i>Actidil</i>	3	B		
Trometamol (Also known as tris hydroxymethyl aminomethane [THAM])		3	B		

Tubocurarine (Curare)	<i>Metubin</i>	2	A		
Tybamate	<i>Benvil, Nospan, etc.</i>	2	A		
Urethane		2	A		
Valdecoxib		4	B	Corrected to be consistent with all NSAIDS	
Valerenic acid		3	A		
Valnoctamide	<i>Nirvanyl</i>	2	A		
Valsartan	<i>Diovan</i>	3	B		
Vardenafil	<i>Levitra</i>	3	A		

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
Vedaprofen		4	B		
Venlafaxine	<i>Efflexor</i>	2	A		
Veralipride	<i>Accional, Veralipril</i>	2	A		
Verapamil	<i>Calan, Isoptin</i>	4	B		
Vercuronium	<i>Norcuron</i>	2	A		
Viloxazine	<i>Catatrol, Vivalan, etc.</i>	2	A		
Vinbarbital	<i>Delvinol</i>	2	A		
Vinylbital	<i>Optanox, Speda</i>	2	A		
Warfarin	<i>Coumadin, Coufarin</i>	5	D		
Xylazine	<i>Rompun, Bay Va 1470</i>	3	B		
Xylometazoline	<i>Otrivin</i>	4	B		
Yohimbine		2	B		

Zafirlukast	<i>Accolate</i>	4	C		
Zaleplon	<i>Sonata</i>	2	A		
Zeranol	<i>Ralgro</i>	4	C		
Ziconotide		1	A		
Zileuton	<i>Zyflo</i>	4	C		
Zilpaterol hydrochloride	<i>Zilpaterol</i>	2	A		
Ziprasidone	<i>Geodon</i>	2	A		
Zolazepam		2	A		
Zolmitriptan	<i>Zomig</i>	3	B		
Zolpidem	<i>Ambien, Stilnox</i>	2	A		
Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
Zomepirac	<i>Zomax</i>	2	B		
Zonisamide	<i>Zonigran</i>	3	B		
Zopiclone	<i>Imovan</i>	2	A		
Zotepine	<i>Lodopin</i>	2	A		
Zuclopenthixol	<i>Ciatyl, Cesordinol</i>	2	A		

UNIFORM CLASSIFICATION OF FOREIGN SUBSTANCES
Version 14.4 (December, 2020)

PENALTY GUIDELINES

© ASSOCIATION OF RACING COMMISSIONERS INTERNATIONAL – 2020.

Association of Racing Commissioners International
2365 Harrodsburg Road, B-450, Lexington, Kentucky, United States
www.arci.com

PENALTY CATEGORY “A”

The following are recommended penalties for violations due to the presence of a drug carrying a Category "A" penalty and for violations of ARCI-011-015 and ARCI-025-015: Prohibited Practices:

LICENSED TRAINER:		
1 st Offense	2 nd LIFETIME offense in any jurisdiction	3 rd LIFETIME offense in any jurisdiction
<ul style="list-style-type: none"> Minimum one-year suspension absent mitigating circumstances. The presence of aggravating factors could be used to impose a maximum of a three-year suspension <p style="text-align: center;">AND</p> <ul style="list-style-type: none"> Minimum fine of \$10,000 or 10% of total purse (greater of the two) absent mitigating circumstances. The presence of aggravating factors could be used to impose a maximum of \$25,000 or 25% of purse (greater of the two). <p style="text-align: center;">AND</p> <ul style="list-style-type: none"> May be referred to the Commission for any further action deemed necessary by the Commission. 	<ul style="list-style-type: none"> Minimum three-year suspension absent mitigating circumstances. The presence of aggravating factors could be used to impose a maximum of license revocation with no reapplication for a three-year period. <p style="text-align: center;">AND</p> <ul style="list-style-type: none"> Minimum fine of \$25,000 or 25% of total purse (greater of the two) absent mitigating circumstances. The presence of aggravating factors could be used to impose a maximum of \$50,000 or 50% purse (greater of the two). <p style="text-align: center;">AND</p> <ul style="list-style-type: none"> May be referred to the Commission for any further action deemed necessary by the Commission. 	<ul style="list-style-type: none"> Minimum five-year suspension absent mitigating circumstances. The presence of aggravating factors could be used to impose a maximum of license revocation with no reapplication for a five-year period. <p style="text-align: center;">AND</p> <ul style="list-style-type: none"> Minimum fine of \$50,000 or 50% of total purse (greater of the two) absent mitigating circumstances. The presence of aggravating factors could be used to impose a maximum of \$100,000 or 100% purse (greater of the two). <p style="text-align: center;">AND</p> <ul style="list-style-type: none"> May be referred to the Commission for any further action deemed necessary by the Commission.
LICENSED OWNER:		
1 st Offense	2 nd LIFETIME offense in owner's stable any jurisdiction	3 rd LIFETIME offense in owner's stable in any jurisdiction
<ul style="list-style-type: none"> Disqualification and loss of purse <p style="text-align: center;">AND</p> <ul style="list-style-type: none"> Horse shall be placed on the Veterinarian's List for 180 days and must pass a commission-approved examination before becoming eligible to be entered. 	<ul style="list-style-type: none"> Disqualification and loss of purse <p style="text-align: center;">AND</p> <ul style="list-style-type: none"> Horse shall be placed on the Veterinarian's List for 180 days and must pass a commission-approved examination before becoming eligible to be entered. 	<ul style="list-style-type: none"> Disqualification, loss of purse and \$50,000 fine <p style="text-align: center;">AND</p> <ul style="list-style-type: none"> Horse shall be placed on the Veterinarian's List for 180 days and must pass a commission-approved examination before becoming eligible to be entered. <p style="text-align: center;">AND</p> <ul style="list-style-type: none"> Referral to the Commission with a recommendation of a suspension for a minimum of 90 days.

PENALTY CATEGORY "B"

The following are recommended penalties for violations due to the presence of a drug carrying Category "B" penalty, for the detection of two or more NSAIDs in a plasma/serum and/or urine sample, the detection of two or more corticosteroids in a plasma/serum and/or urine sample subject to the provisions set forth in ARCI-011-020(E) and ARCI-025-020(E) and for violations of the established levels for total carbon dioxide:

Version 14.4, December 2020

LICENSED TRAINER:		
1 st Offense	2 nd offense (365-day period) in any jurisdiction	3 rd offense (365-day period) in any jurisdiction
<ul style="list-style-type: none"> Minimum 15-day suspension absent mitigating circumstances. The presence of aggravating factors could be used to impose a maximum of a 60-day suspension <p style="text-align: center;">AND</p> <ul style="list-style-type: none"> Minimum fine of \$500 absent mitigating circumstances. The presence of aggravating factors could be used to impose a maximum fine of \$1,000. 	<ul style="list-style-type: none"> Minimum 30-day suspension absent mitigating circumstances. The presence of aggravating factors could be used to impose a maximum of a 180-day suspension <p style="text-align: center;">AND</p> <ul style="list-style-type: none"> Minimum fine of \$1,000 absent mitigating circumstances. The presence of aggravating factors could be used to impose a maximum fine of \$2,500. 	<ul style="list-style-type: none"> Minimum 60-day suspension absent mitigating circumstances. The presence of aggravating factors could be used to impose a maximum of a one-year suspension. <p style="text-align: center;">AND</p> <ul style="list-style-type: none"> Minimum fine of \$2,500 absent mitigating circumstances. The presence of aggravating factors could be used to impose a maximum of \$5,000 or 5% purse (greater of the two). <p style="text-align: center;">AND</p> <ul style="list-style-type: none"> May be referred to the Commission for any further action deemed necessary by the Commission.
LICENSED OWNER:		
1 st Offense	2 nd offense (365-day period) in owner's stable any jurisdiction	3 rd offense (365-day period) in owner's stable in any jurisdiction
<ul style="list-style-type: none"> Disqualification and loss of purse [in the absence of mitigating circumstances]* <p style="text-align: center;">AND</p> <ul style="list-style-type: none"> Horse must pass a commission-approved examination before becoming eligible to be entered. 	<ul style="list-style-type: none"> Disqualification and loss of purse [in the absence of mitigating circumstances]* <p style="text-align: center;">AND</p> <ul style="list-style-type: none"> Horse must pass a commission-approved examination before becoming eligible to be entered. 	<ul style="list-style-type: none"> Disqualification, loss of purse, and in the absence of mitigating circumstances a \$5,000 fine.* <p style="text-align: center;">AND</p> <ul style="list-style-type: none"> Horse shall be placed on the Veterinarian's List for 45 days and must pass a commission-approved examination before becoming eligible to be entered.

PENALTY CATEGORY "C"

The following are recommended penalties for violations due to the presence of a drug carrying a Category "C" penalty and overages for permitted NSAIDs and furosemide: *(All concentrations are for measurements in serum or plasma.)*

LICENSED TRAINER	Furosemide (>100 ng/ml) and/or no furosemide when identified as administered	Phenylbutazone (>0.3 mcg/ml) Flunixin (> 5.0 ng/ml) Ketoprofen (> 2.0 ng/ml) and CLASS C Violations
1 st Offense (365-day period) in any jurisdiction	Minimum of a written warning to maximum fine of \$500	Minimum fine of \$1,000 absent mitigating circumstances
2 nd Offense (365-day period) in any jurisdiction	Minimum of a written warning to maximum fine of \$750	Minimum fine of \$1,500 and 15-day suspension absent mitigating circumstances
3 rd Offense (365-day period) in any jurisdiction	Minimum fine of \$500 to a maximum fine of \$1,000	Minimum fine of \$2,500 and 30-day suspension absent mitigating circumstances
LICENSED OWNER	Furosemide (>100 ng/ml) and/or no furosemide when identified as administered	Phenylbutazone (>0.3 mcg/ml) Flunixin (> 5.0 ng/ml) Ketoprofen (> 2.0 ng/ml) and CLASS C Violations
1 st Offense (365-day period) in any jurisdiction	Horse may be required to pass commission-approved examination before being eligible to run	Disqualification and loss of purse in the absence of mitigating circumstances. Horse must pass commission-approved examination before being eligible to run.
2 nd Offense (365-day period) in any jurisdiction	Horse may be required to pass commission-approved examination before being eligible to run	Disqualification and loss of purse in the absence of mitigating circumstances. If same horse, placed on veterinarian's list for 45 days, must pass commission-approved examination before being eligible to run
3 rd Offense (365-day period) in any jurisdiction	Disqualification and loss of purse. Horse must pass commission-approved examination before being eligible to run	Disqualification and loss of purse in the absence of mitigating circumstances. Minimum \$5,000 fine. If same horse, placed on veterinarian's list for 60 days, must pass commission-approved examination before being eligible to run

After a two-year period, if the licensee has had no further violations, any penalty due to an overage in the 2.0-5.0 category will be expunged from the licensee's record for penalty purposes.

PENALTY CATEGORY "D"

The recommended penalty for a violation involving a drug that carries a Category "D" penalty is a written warning to the trainer and owner. Multiple violations may result in fines and/or suspension.

MMV Point System
Multiple Medication Violation Model Rule. ARCI-011-020
(B)(13)

Officials are advised to check a licensee's ARCI regulatory record to see if multiple medication violations should be considered as an aggravating factor in the determination of an appropriate penalty.

(1) Multiple Medication Violations (MMV)

- (a) A trainer who receives a penalty for a medication violation based upon a horse testing positive for a Class 1-5 medication with Penalty Class A-C, as provided in the most recent version of the ARCI Uniform Classification Guidelines for Foreign Substances, or similar state regulatory guidelines, shall be assigned points as follows:

Penalty Class	Points If Controlled Therapeutic Substance	Points If Non-Controlled Substance
Class A	N/A	6
Class B	2	4
Class C	½ for first violation with an additional ½ point for each additional violation within 365 days ¹	1 for first violation with an additional ½ point for each additional violation within 365 days
Class D	0	0

¹ Points for NSAID violations only apply when the primary threshold of the NSAID is exceeded. Points are not to be separately assigned for a stacking violation.

If the Stewards or Commission determine that the violation is due to environmental contamination, they may assign lesser or no points against the trainer based upon the specific facts of the case.

- (b) The points assigned to a medication violation by the Stewards or Commission ruling shall be included in the ARCI official database. The ARCI shall record points consistent with Section 13(a) including when appropriate, a designation that points have been suspended for the medication violation. Points assigned by such regulatory ruling shall reflect, in the case of multiple

positive tests as described in paragraph (d), whether they constitute a single violation. The Stewards' or Commission Ruling shall be posted on the official website of the Commission and within the official database of the Association of Racing Commissioners International. If an appeal is pending, that fact shall be noted in such Ruling. No points shall be applied until a final adjudication of the enforcement of any such violation.

- (c) A trainer's cumulative points for violations in all racing jurisdictions shall be maintained by the ARCI. Once all appeals are waived or exhausted, the points shall immediately become part of the trainer's official ARCI record and shall be considered by the Commission in its determination to subject the trainer to the mandatory enhanced penalties by the Stewards or Commission as provided in this regulation.
- (d) Multiple positive tests for the same medication incurred by a trainer prior to delivery of official notice by the commission may be treated as a single violation. In the case of a positive test indicating multiple substances found in a single post-race sample, the Stewards may treat each substance found as an individual violation for which points will be assigned, depending upon the facts and circumstances of the case.
- (e) The official ARCI record shall be used to advise the Stewards or Commission of a trainer's past record of violations and cumulative points. Nothing in this administrative regulation shall be construed to confer upon a licensed trainer the right to appeal a violation for which all remedies have been exhausted or for which the appeal time has expired as provided by applicable law.
- (f) The Stewards or Commission shall consider all points for violations in all racing jurisdictions as contained in the trainer's official ARCI record when determining whether the mandatory enhancements provided in this regulation shall be imposed.
- (g) In addition to the penalty for the underlying offense, the following enhancements shall be imposed upon a licensed trainer based upon the cumulative points contained in his/her official ARCI record:

Points	Suspension in days
5-5.5	15 to 30
6-8.5	30 to 60
9-10.5	90 to 180
11 or more	180 to 360

MMV penalties are not a substitute for the current penalty system and are intended to be an additional uniform penalty when the licensee:

- (i) Has had more than one medication violation for the relevant time period, and (ii)
Exceeds the permissible number of points.

The Stewards and Commission shall consider aggravating and mitigating circumstances, including the trainer's prior record for medication violations, when determining the appropriate penalty for the underlying offense. The MMP is intended to be a separate and additional penalty for a pattern of violations.

- (h) The suspension periods as provided in Section 13(g) shall run consecutive to any suspension imposed for the underlying offense.
- (i) The Stewards' or Commission Ruling shall distinguish between the penalty for the underlying offense and any enhancement based upon a Stewards or Commission review of the trainer's cumulative points and regulatory record, which may be considered an aggravating factor in a case.
- (j) Points shall expire as follows:

Penalty Classification	Time to Expire
A	3 years
B	2 years
C	1 year

In the case of a medication violation that results in a suspension, any points assessed expire on the anniversary date of the date the suspension is completed.

#####

REVISIONS TO ARCI UNIFORM CLASSIFICATION GUIDELINES FOR FOREIGN SUBSTANCES

Version	Date	Drug/Substance	Notes
14.2	September 2020	Medroxyprogesterone	Replaced methoxyprogesterone as probable typo
14.2	September 2020	Medroxyprogesterone	Added as Drug Class 3, Penalty Class B.
14.2	September 2020	Methoxyprogesterone	Removed as drug does not exist 14.2
September 2020			
Methoxyprogesterone Removed Asterisk Language on Permitted Nsaids			
“*If the trainer has not had more than one violation within the previous two years, the Stewards/Judges are encouraged to issue a warning in lieu of a fine provided the reported level is below 3.0 mcg/ml absent of aggravating factors.”			
14.3	September 2020	Medroxyprogesterone	Moved to correct location alphabetically
14.4	December 2020	Alpha pyrrolidinovalerophenone	Added as Drug Class 1, Penalty Class A
14.4	December 2020	Aripiprazole	Added as Drug Class 2, Penalty Class A
14.4	December 2020	Arsenic	Added as Drug Class 3, Penalty Class B
14.4	December 2020	Diisopropylamine	Added as Drug Class 2, Penalty Class B
14.4	December 2020	Etofenamate	Added as Drug Class 4, Penalty Class B
14.4	December 2020	Flufenamic Acid	Changed to Drug Class 4, Penalty B
14.4	December 2020	Harpagoside	Added as Drug Class 4, Penalty B
14.4	December 2020	Hypoxia-inducible factor (HIF) activators	Changed from Drug Class 3, Penalty A to Drug Class 1, Penalty A
14.4	December 2020	Hypoxia-inducible factor (HIF) stabilizers (e.g. IOX-2)	Added as Drug Class 1, Penalty A
14.4	December 2020	Molidustat	Added as Drug Class 1, Penalty A
14.4	December 2020	Norethisterone(norethindrone)	Added as Drug Class 4, Penalty B
14.4	December 2020	Oliceridine	Added as Drug Class 1, Penalty A
14.4	December 2020	Oripavine	Added as Drug Class 2, Penalty A
14.4	December 2020	Parecoxib	Added as Drug Class 4, Penalty B
14.4	December 2020	Pregabalin	Added as Drug Class 3, Penalty B
14.4	December 2020	Tapentadol	Added as Drug Class 1, Penalty A
14.4	December 2020	Trometamol (Also known as THAM)	Added as Drug Class 3, Penalty B
14.4	December 2020	Valdecoxib	Changed from Drug Class 2, Penalty B to Drug Class 4, Penalty B

NOTICE OF PUBLIC HEARING

RECEIVED
SEP 08 2021

The Arkansas Racing Commission will meet on October 14, 2021, at 11:00 a.m. in the Commission office located at 1515 West Seventh Street, Suite 500, Little Rock, Arkansas, to consider the adoption of the following rule changes:

(1) Thoroughbred Rule 1217 Medication and Prohibited Foreign Substances. Proposed amendment extends the prohibition on administration of clenbuterol and other B-2 agonists from 60 to 120 days before the race and changes other provisions of the existing Rule to more closely align with current industry practices and the latest version of industry model rules.

(2) Thoroughbred Rule 1217.1 Anabolic Steroids. Proposed amendment is to more closely align with current model rules and industry practices.

(3) Thoroughbred Rule 1217.5 Uniform Guidelines for Foreign Substances and Recommended Penalties Model Rule. Proposed amendment is the most current updated Rule from the Association of Racing Commissioners International. The ARCI guidelines are updated periodically.

(4) Thoroughbred Rule 1232(5) Medication Furosemide (Lasix). Proposed amendment specifies the penalty for use of Lasix in a race designated as Lasix-free by the franchise holder.

(5) Thoroughbred Rule 2169 Jockey Mount Fees. This proposed amendment provides for a specified payment to a jockey who finishes in fourth place and sets a minimum dollar amount jockey fee for finishing second or third in races with a purse less than \$25,000.

(6) Thoroughbred Rule 2426 Claiming. This proposed amendment allows an owner to more easily claim a horse and removes some of the previous minor requirements for eligibility for claiming horses. It also changes the time period for use of a claiming certificate until 24 hours after the application was approved by the Stewards.

(7) Thoroughbred Rule 2426-A Claiming. This proposed amendment allows, subject to certain conditions, an owner to take advantage of a second waiver, making a horse ineligible to be claimed for a second race, after a first waiver has been executed under the existing Rule.

(8) Thoroughbred Rule 2430 Claiming. This proposed amendment limits claims by a stable / owner which has the same trainer.

(9) Thoroughbred Rule 2440 Claiming. This proposed amendment addresses claiming and timing for transfer of title to a claimed horse to more clearly align with other Rules allowing revocation and voiding of claims in certain circumstances under other Rules.

(10) Thoroughbred Rule 2458 Claiming. This proposed amendment allows Racing Secretary to approve, in certain cases, exceptions to Rule 2458(a) waiting period for eligibility of a horse to run at other racetracks after being claimed at Oaklawn.

Any persons wishing to speak for or against any of the above-proposed rule changes should appear at the meeting on October 14, 2021, and they will be given the opportunity to express their views. Persons wishing to submit written comments on the above-proposed rule changes should send them to the Arkansas Racing Commission, P.O. Box 3076, Little Rock, Arkansas 72203, prior to the close of business on Tuesday, October 12, 2021. Copies of the complete text of the proposed rule changes can be obtained from the Racing Commission office during normal business hours and from the Secretary of State's office.

Arkansas Democrat Gazette

STATEMENT OF LEGAL ADVERTISING

MITCHELL WILLIAMS SELIG GATES
425 W CAPITOL AVE
LITTLE ROCK AR 72201

REMIT TO:
ARKANSAS DEMOCRAT-GAZETTE INC.
P.O. BOX 2221
LITTLE ROCK, AR 72203

ATTN: Byron Freeland
DATE : 08/29/21 INVOICE #: 3248550
ACCT #: L1055177 P.O. #:

For Billing Questions call: 501-399-3660

STATE OF ARKANSAS, }
COUNTY OF PULASKI, } ss.

AD COPY

I, Charles A McNeice Jr, do solemnly swear that I am the Business Manager of the Arkansas Democrat-Gazette, a daily newspaper printed and published in said County, State of Arkansas; that I was so related to this publication at and during the publication of the annexed legal advertisement the matter of:

hearing
pending in the Court, in said County, and at the dates of the several publications of said advertisement stated below, and that during said periods and at said dates, said newspaper was printed and had a bona fide circulation in said County; that said newspaper had been regularly printed and published in said County, and had a bona fide circulation therein for the period of one month before the date of the first publication of said advertisement; and that said advertisement was published in the regular daily issues of said newspaper as stated below.

RECEIVED
SEP 08 2021
BUREAU OF
LEGISLATIVE RESEARCH

DATE	DAY	LINAGE	RATE	DATE	DAY	LINAGE	RATE
08/27	Fri	143	1.35				
08/28	Sat	143	1.35				
08/29	Sun	143	1.57				

TOTAL COST ----- 610.61
Billing Ad #: 75458160


Subscribed and sworn to before me on this 30

day of Aug, 2021


Signature of Notary Public

OFFICIAL SEAL - #12347408
DEANNA GRIFFIN
NOTARY PUBLIC-ARKANSAS
PULASKI COUNTY
MY COMMISSION EXPIRES: 03-30-26

Arkansas I

STATEMENTS

THIS PAGE USED FOR ALL

PAC

at  Gazette

L ADVERTISING

AD COPY SPACE AS NEEDED.

BLANK

NOTICE OF PUBLIC HEARING
The Arkansas Racing Commission will meet on October 14, 2021, at 11:00 a.m. in the Commission office located at 1515 West Seventh Street, Suite 600, Little Rock, Arkansas, to consider the adoption of the following rule changes:

(1) Thoroughbred Rule 1217: Medication and Prohibited Foreign Substances. Proposed amendment extends the prohibition on administration of clenbuterol and other B-2 agonists from 60 to 120 days before the race and changes other provisions of the existing Rule to more closely align with current industry practices and the latest version of industry model rules.

(2) Thoroughbred Rule 1217.1: Anabolic Steroids. Proposed amendment is to more closely align with current model rules and industry practices.

(3) Thoroughbred Rule 1217.5: Uniform Guidelines for Foreign Substances and Recommended Penalties Model Rule. Proposed amendment is the most current updated Rule from the Association of Racing Commissioners International. The ARC guidelines are updated periodically.

(4) Thoroughbred Rule 1232(6): Medication Fluorenilide (Lasix). Proposed amendment specifies the penalty for use of Lasix in a race designated as Lasix-free by the franchise holder.

(5) Thoroughbred Rule 2169: Jockey Mount Fees. This proposed amendment provides for a specified payment to a jockey who finishes in fourth place and sets a minimum dollar amount jockey fee for finishing second or third in races with a purse less than \$25,000.

(6) Thoroughbred Rule 2426: Claiming. This proposed amendment allows an owner to more easily claim a horse and removes some of the previous minor requirements for eligibility for claiming horses. It also changes the time period for use of a claiming certificate until 24 hours after the application was approved by the Stewards.

(7) Thoroughbred Rule 2426-A: Claiming. This proposed amendment allows, subject to certain conditions, an owner to take advantage of a second waiver, making a horse ineligible to be claimed for a second race, after a first waiver has been executed under the existing Rule.

(8) Thoroughbred Rule 2430: Claiming. This proposed amendment limits claims by a stable / owner which has the same trainer.

(9) Thoroughbred Rule 2440: Claiming. This proposed amendment addresses claiming and timing for transfer of title to a claimed horse to more clearly align with other Rules allowing revocation and voiding of claims in certain circumstances under other Rules.

(10) Thoroughbred Rule 2458: Claiming. This proposed amendment allows Racing Secretary to approve, in certain cases, exceptions to Rule 2458(a) waiting period for eligibility of a horse to run at other racetracks after being claimed at Oaklawn.

Any persons wishing to speak for or against any of the above proposed rule changes should appear at the meeting on October 14, 2021, and they will be given the opportunity to express their views. Persons wishing to submit written comments on the above proposed rule changes should send them to the Arkansas Racing Commission, P.O. Box 3076, Little Rock, Arkansas 72203, prior to the close of business on Tuesday, October 12, 2021. Copies of the complete text of the proposed rule changes can be obtained from the Racing Commission office during normal business hours and from the Secretary of State's office.

754661601

Susie Luce

From: Susie Luce <SLuce@mwlaw.com> on behalf of Byron Freeland <BFreeland@mwlaw.com>
Sent: Friday, August 27, 2021 9:37 AM
To: Gwen Nguyen
Subject: RE: Notice of Public Hearing (Arkansas Racing Commission) Rule 1217.5 PART 2 of 2
Attachments: completed Thoroughbred Rule 1217.5 Arkansas Register SOS Proposed Rule Cover Sheet.pdf

Here is Part 2 of 2 of Thoroughbred Rule 1217.5. Please confirm receipt and hopefully that all proposed Thoroughbred Rule Changes will be placed on the website today (fingers crossed!). Thank you so much for your assistance with this!

MITCHELL WILLIAMS

Susie Luce | Assistant to Ken Cook and Byron Freeland
T 501.370.4232 | F 501.918.7232
sluce@mwlaw.com | MitchellWilliamsLaw.com
425 W. Capitol Ave. | Ste. 1800 | Little Rock, AR 72201
Mitchell, Williams, Selig, Gates & Woodyard, P.L.L.C.

RECEIVED
SEP 08 2021
BUREAU OF
LEGISLATIVE RESEARCH

From: Gwen Nguyen <gwen.nguyen@sos.arkansas.gov>
Sent: Friday, August 27, 2021 8:55 AM
To: Byron Freeland <BFreeland@mwlaw.com>
Subject: RE: Notice of Public Hearing (Arkansas Racing Commission) Rule 1217.5 PART 1 of 2

Got it!

From: Susie Luce <SLuce@mwlaw.com> On Behalf Of Byron Freeland
Sent: Friday, August 27, 2021 8:38 AM
To: Gwen Nguyen <gwen.nguyen@sos.arkansas.gov>
Subject: RE: Notice of Public Hearing (Arkansas Racing Commission) Rule 1217.5 PART 1 of 2

External Message

Here is Part 1 of Thoroughbred Rule 1217.5. Please acknowledge receipt and ability to access this one, and then I will send Part 2! Thanks!

MITCHELL WILLIAMS

Susie Luce | Assistant to Ken Cook and Byron Freeland
T 501.370.4232 | F 501.918.7232
sluce@mwlaw.com | MitchellWilliamsLaw.com

425 W. Capitol Ave. | Ste. 1800 | Little Rock, AR 72201
Mitchell, Williams, Selig, Gates & Woodyard, P.L.L.C.

From: Gwen Nguyen <gwen.nguyen@sos.arkansas.gov>
Sent: Friday, August 27, 2021 8:09 AM
To: Byron Freeland <BFreeland@mwlaw.com>
Subject: RE: Notice of Public Hearing (Arkansas Racing Commission)

You can send them in several pieces to break it apart. Thanks!

From: Susie Luce <SLuce@mwlaw.com> **On Behalf Of** Byron Freeland
Sent: Thursday, August 26, 2021 4:18 PM
To: Gwen Nguyen <gwen.nguyen@sos.arkansas.gov>
Subject: RE: Notice of Public Hearing (Arkansas Racing Commission)

External Message

Thanks, ma'am! We need to get these items published to your website quickly as the Notice begins publication in the paper tomorrow.

MITCHELL WILLIAMS

Susie Luce | Assistant to Ken Cook and Byron Freeland
T 501.370.4232 | F 501.918.7232
sluce@mwlaw.com | MitchellWilliamsLaw.com
425 W. Capitol Ave. | Ste. 1800 | Little Rock, AR 72201
Mitchell, Williams, Selig, Gates & Woodyard, P.L.L.C.

From: Gwen Nguyen <gwen.nguyen@sos.arkansas.gov>
Sent: Thursday, August 26, 2021 3:36 PM
To: Byron Freeland <BFreeland@mwlaw.com>
Subject: RE: Notice of Public Hearing (Arkansas Racing Commission)

I don't know if I can access that. I really don't know what to tell you. Let me ask IT and will get back with you.

From: Susie Luce <SLuce@mwlaw.com> **On Behalf Of** Byron Freeland
Sent: Thursday, August 26, 2021 3:26 PM
To: Gwen Nguyen <gwen.nguyen@sos.arkansas.gov>
Subject: RE: Notice of Public Hearing (Arkansas Racing Commission)

External Message

I can also send it via secure large-file-send email, MIMECAST, but I'm not sure if you can access that?

MITCHELL WILLIAMS

Susie Luce | Assistant to Ken Cook and Byron Freeland
T. 501.370.4232 | F 501.918.7232
sluce@mwlaw.com | MitchellWilliamsLaw.com
425 W. Capitol Ave. | Ste. 1800 | Little Rock, AR 72201
Mitchell, Williams, Selig, Gates & Woodyard, P.L.L.C.

From: Susie Luce <SLuce@mwlaw.com> **On Behalf Of** Byron Freeland
Sent: Thursday, August 26, 2021 3:18 PM
To: Gwen Nguyen <gwen.nguyen@sos.arkansas.gov>
Subject: RE: Notice of Public Hearing (Arkansas Racing Commission)

Should I send it in two parts or would you prefer that I have it hand delivered on a disc? What do you recommend?

MITCHELL WILLIAMS

Susie Luce | Assistant to Ken Cook and Byron Freeland
T 501.370.4232 | F 501.918.7232
sluce@mwlaw.com | MitchellWilliamsLaw.com
425 W. Capitol Ave. | Ste. 1800 | Little Rock, AR 72201
Mitchell, Williams, Selig, Gates & Woodyard, P.L.L.C.

From: Gwen Nguyen <gwen.nguyen@sos.arkansas.gov>
Sent: Thursday, August 26, 2021 3:13 PM
To: Byron Freeland <BFreeland@mwlaw.com>
Subject: RE: Notice of Public Hearing (Arkansas Racing Commission)

No I do not have that one and have not received an email for it either.

From: Susie Luce <SLuce@mwlaw.com> **On Behalf Of** Byron Freeland
Sent: Thursday, August 26, 2021 2:59 PM
To: Gwen Nguyen <gwen.nguyen@sos.arkansas.gov>
Subject: RE: Notice of Public Hearing (Arkansas Racing Commission)

External Message

I had to send one rule 1217.5 separately because it was too large to include in the original email. Did it get included inadvertently in the original email, because I also sent it separately?

MITCHELL WILLIAMS

Susie Luce | Assistant to Ken Cook and Byron Freeland
T 501.370.4232 | F 501.918.7232
sluce@mwlaw.com | MitchellWilliamsLaw.com
425 W. Capitol Ave. | Ste. 1800 | Little Rock, AR 72201
Mitchell, Williams, Selig, Gates & Woodyard, P.L.L.C.

From: Gwen Nguyen <gwen.nguyen@sos.arkansas.gov>
Sent: Thursday, August 26, 2021 2:53 PM
To: Byron Freeland <BFreeland@mwlaw.com>
Subject: RE: Notice of Public Hearing (Arkansas Racing Commission)

Just making sure, you said 9 proposed rules. You attached 10 rules and the Notice also has 10 rules. Please advise!

From: Susie Luce <SLuce@mwlaw.com> On Behalf Of Byron Freeland
Sent: Thursday, August 26, 2021 2:22 PM
To: Arkansas Register <ArkansasRegister@sos.arkansas.gov>
Subject: Notice of Public Hearing (Arkansas Racing Commission)

External Message

Please see attached Notice of Public Hearing (Word and .pdf formats) and 9 proposed rule changes with cover sheets for publication to the SOS website. I have one more proposed rule change with cover sheet to send separately due to size.

Please confirm receipt of this email.

Thanks!

MITCHELL WILLIAMS

Byron Freeland
T 501.688.8810 | F 501.918.7810
bfreeland@mwlaw.com | MitchellWilliamsLaw.com
425 W. Capitol Ave. | Ste. 1800 | Little Rock, AR 72201
Mitchell, Williams, Selig, Gates & Woodyard, P.L.L.C.

Confidentiality Notice: This electronic mail transmission and any attachments may constitute an attorney-client communication that is privileged at law. It is not intended for transmission to, or receipt by, any unauthorized persons. If you have received this electronic mail transmission in error, please delete it from your system without copying it, and notify the sender by reply e-mail or by calling (501) 688-8800 Little Rock, AR (479) 464-8350 Rogers, AR (512) 480-5100 Austin, TX or (970) 938-6262 Jonesboro, AR so that our address record can be corrected.